<html xmlns:v="urn:schemas-microsoft-com:vml"
xmlns:o="urn:schemas-microsoft-com:office:office"
xmlns:w="urn:schemas-microsoft-com:office:word"
xmlns:m="http://schemas.microsoft.com/office/2004/12/omml"
xmlns="http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=ProgId content=Word.Document>
<meta name=Generator content="Microsoft Word 15">
<meta name=Originator content="Microsoft Word 15">
<link rel=File-List href="psoriasis_files/filelist.xml">
<!--[if gte mso 9]><xml>
 <o:DocumentProperties>
  <o:Author>Emmanuel Okonkwo</o:Author>
  <o:Template>Normal</o:Template>
  <o:LastAuthor>Emmanuel Okonkwo</o:LastAuthor>
  <o:Revision>1</o:Revision>
  <o:TotalTime>1</o:TotalTime>
  <o:Created>2024-11-22T22:29:00Z</o:Created>
  <o:LastSaved>2024-11-22T22:30:00Z</o:LastSaved>
  <o:Pages>29</o:Pages>
  <o:Words>14997</o:Words>
  <o:Characters>85483</o:Characters>
  <o:Lines>712</o:Lines>
  <o:Paragraphs>200</o:Paragraphs>
  <o:CharactersWithSpaces>100280</o:CharactersWithSpaces>
  <o:Version>16.00</o:Version>
 </o:DocumentProperties>
 <o:OfficeDocumentSettings>
  <o:AllowPNG/>
 </o:OfficeDocumentSettings>
</xml><![endif]-->
<link rel=themeData href="psoriasis_files/themedata.thmx">
<link rel=colorSchemeMapping href="psoriasis_files/colorschememapping.xml">
<!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:SpellingState>Clean</w:SpellingState>
  <w:GrammarState>Clean</w:GrammarState>
  <w:TrackMoves>false</w:TrackMoves>
  <w:TrackFormatting/>
  <w:PunctuationKerning/>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:DoNotPromoteQF/>
  <w:LidThemeOther>EN-GB</w:LidThemeOther>
  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>
  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
  <w:Compatibility>
   <w:BreakWrappedTables/>
   <w:SnapToGridInCell/>
   <w:WrapTextWithPunct/>
   <w:UseAsianBreakRules/>
   <w:DontGrowAutofit/>
   <w:SplitPgBreakAndParaMark/>
   <w:EnableOpenTypeKerning/>
   <w:DontFlipMirrorIndents/>
   <w:OverrideTableStyleHps/>
  </w:Compatibility>
  <m:mathPr>
   <m:mathFont m:val="Cambria Math"/>
   <m:brkBin m:val="before"/>
   <m:brkBinSub m:val="&#45;-"/>
   <m:smallFrac m:val="off"/>
   <m:dispDef/>
   <m:lMargin m:val="0"/>
   <m:rMargin m:val="0"/>
   <m:defJc m:val="centerGroup"/>
   <m:wrapIndent m:val="1440"/>
   <m:intLim m:val="subSup"/>
   <m:naryLim m:val="undOvr"/>
  </m:mathPr></w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="false"
  DefSemiHidden="false" DefQFormat="false" DefPriority="99"
  LatentStyleCount="376">
  <w:LsdException Locked="false" Priority="0" QFormat="true" Name="Normal"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 1"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 2"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 3"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 4"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 5"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 6"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 7"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 8"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="heading 9"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 6"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 7"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 8"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index 9"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 1"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 2"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 3"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 4"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 5"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 6"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 7"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 8"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" Name="toc 9"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Normal Indent"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="footnote text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="annotation text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="header"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="footer"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="index heading"/>
  <w:LsdException Locked="false" Priority="35" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="caption"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="table of figures"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="envelope address"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="envelope return"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="footnote reference"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="annotation reference"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="line number"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="page number"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="endnote reference"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="endnote text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="table of authorities"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="macro"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="toa heading"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Bullet"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Number"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Bullet 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Bullet 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Bullet 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Bullet 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Number 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Number 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Number 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Number 5"/>
  <w:LsdException Locked="false" Priority="10" QFormat="true" Name="Title"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Closing"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Signature"/>
  <w:LsdException Locked="false" Priority="1" SemiHidden="true"
   UnhideWhenUsed="true" Name="Default Paragraph Font"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text Indent"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Continue"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Continue 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Continue 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Continue 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="List Continue 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Message Header"/>
  <w:LsdException Locked="false" Priority="11" QFormat="true" Name="Subtitle"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Salutation"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Date"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text First Indent"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text First Indent 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Note Heading"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text Indent 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Body Text Indent 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Block Text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Hyperlink"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="FollowedHyperlink"/>
  <w:LsdException Locked="false" Priority="22" QFormat="true" Name="Strong"/>
  <w:LsdException Locked="false" Priority="20" QFormat="true" Name="Emphasis"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Document Map"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Plain Text"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="E-mail Signature"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Top of Form"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Bottom of Form"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Normal (Web)"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Acronym"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Address"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Cite"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Code"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Definition"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Keyboard"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Preformatted"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Sample"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Typewriter"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="HTML Variable"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Normal Table"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="annotation subject"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="No List"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Outline List 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Outline List 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Outline List 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Simple 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Simple 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Simple 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Classic 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Classic 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Classic 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Classic 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Colorful 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Colorful 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Colorful 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Columns 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 6"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 7"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Grid 8"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 4"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 5"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 6"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 7"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table List 8"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table 3D effects 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table 3D effects 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table 3D effects 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Contemporary"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Elegant"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Professional"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Subtle 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Subtle 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Web 1"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Web 2"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Web 3"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Balloon Text"/>
  <w:LsdException Locked="false" Priority="39" Name="Table Grid"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Table Theme"/>
  <w:LsdException Locked="false" SemiHidden="true" Name="Placeholder Text"/>
  <w:LsdException Locked="false" Priority="1" QFormat="true" Name="No Spacing"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 1"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 1"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 1"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 1"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 1"/>
  <w:LsdException Locked="false" SemiHidden="true" Name="Revision"/>
  <w:LsdException Locked="false" Priority="34" QFormat="true"
   Name="List Paragraph"/>
  <w:LsdException Locked="false" Priority="29" QFormat="true" Name="Quote"/>
  <w:LsdException Locked="false" Priority="30" QFormat="true"
   Name="Intense Quote"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 1"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 1"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 1"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 1"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 1"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 1"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 2"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 2"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 2"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 2"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 2"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 2"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 2"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 2"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 2"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 2"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 2"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 3"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 3"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 3"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 3"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 3"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 3"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 3"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 3"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 3"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 3"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 3"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 4"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 4"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 4"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 4"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 4"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 4"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 4"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 4"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 4"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 4"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 4"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 5"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 5"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 5"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 5"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 5"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 5"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 5"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 5"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 5"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 5"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 5"/>
  <w:LsdException Locked="false" Priority="60" Name="Light Shading Accent 6"/>
  <w:LsdException Locked="false" Priority="61" Name="Light List Accent 6"/>
  <w:LsdException Locked="false" Priority="62" Name="Light Grid Accent 6"/>
  <w:LsdException Locked="false" Priority="63" Name="Medium Shading 1 Accent 6"/>
  <w:LsdException Locked="false" Priority="64" Name="Medium Shading 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="65" Name="Medium List 1 Accent 6"/>
  <w:LsdException Locked="false" Priority="66" Name="Medium List 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="67" Name="Medium Grid 1 Accent 6"/>
  <w:LsdException Locked="false" Priority="68" Name="Medium Grid 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="69" Name="Medium Grid 3 Accent 6"/>
  <w:LsdException Locked="false" Priority="70" Name="Dark List Accent 6"/>
  <w:LsdException Locked="false" Priority="71" Name="Colorful Shading Accent 6"/>
  <w:LsdException Locked="false" Priority="72" Name="Colorful List Accent 6"/>
  <w:LsdException Locked="false" Priority="73" Name="Colorful Grid Accent 6"/>
  <w:LsdException Locked="false" Priority="19" QFormat="true"
   Name="Subtle Emphasis"/>
  <w:LsdException Locked="false" Priority="21" QFormat="true"
   Name="Intense Emphasis"/>
  <w:LsdException Locked="false" Priority="31" QFormat="true"
   Name="Subtle Reference"/>
  <w:LsdException Locked="false" Priority="32" QFormat="true"
   Name="Intense Reference"/>
  <w:LsdException Locked="false" Priority="33" QFormat="true" Name="Book Title"/>
  <w:LsdException Locked="false" Priority="37" SemiHidden="true"
   UnhideWhenUsed="true" Name="Bibliography"/>
  <w:LsdException Locked="false" Priority="39" SemiHidden="true"
   UnhideWhenUsed="true" QFormat="true" Name="TOC Heading"/>
  <w:LsdException Locked="false" Priority="41" Name="Plain Table 1"/>
  <w:LsdException Locked="false" Priority="42" Name="Plain Table 2"/>
  <w:LsdException Locked="false" Priority="43" Name="Plain Table 3"/>
  <w:LsdException Locked="false" Priority="44" Name="Plain Table 4"/>
  <w:LsdException Locked="false" Priority="45" Name="Plain Table 5"/>
  <w:LsdException Locked="false" Priority="40" Name="Grid Table Light"/>
  <w:LsdException Locked="false" Priority="46" Name="Grid Table 1 Light"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark"/>
  <w:LsdException Locked="false" Priority="51" Name="Grid Table 6 Colorful"/>
  <w:LsdException Locked="false" Priority="52" Name="Grid Table 7 Colorful"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 1"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 1"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 1"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 1"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 1"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 1"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 2"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 2"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 2"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 2"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 2"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 2"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 3"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 3"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 3"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 3"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 3"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 3"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 4"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 4"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 4"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 4"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 4"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 4"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 5"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 5"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 5"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 5"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 5"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 5"/>
  <w:LsdException Locked="false" Priority="46"
   Name="Grid Table 1 Light Accent 6"/>
  <w:LsdException Locked="false" Priority="47" Name="Grid Table 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="48" Name="Grid Table 3 Accent 6"/>
  <w:LsdException Locked="false" Priority="49" Name="Grid Table 4 Accent 6"/>
  <w:LsdException Locked="false" Priority="50" Name="Grid Table 5 Dark Accent 6"/>
  <w:LsdException Locked="false" Priority="51"
   Name="Grid Table 6 Colorful Accent 6"/>
  <w:LsdException Locked="false" Priority="52"
   Name="Grid Table 7 Colorful Accent 6"/>
  <w:LsdException Locked="false" Priority="46" Name="List Table 1 Light"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark"/>
  <w:LsdException Locked="false" Priority="51" Name="List Table 6 Colorful"/>
  <w:LsdException Locked="false" Priority="52" Name="List Table 7 Colorful"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 1"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 1"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 1"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 1"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 1"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 1"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 2"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 2"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 2"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 2"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 2"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 2"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 3"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 3"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 3"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 3"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 3"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 3"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 4"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 4"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 4"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 4"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 4"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 4"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 5"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 5"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 5"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 5"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 5"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 5"/>
  <w:LsdException Locked="false" Priority="46"
   Name="List Table 1 Light Accent 6"/>
  <w:LsdException Locked="false" Priority="47" Name="List Table 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="48" Name="List Table 3 Accent 6"/>
  <w:LsdException Locked="false" Priority="49" Name="List Table 4 Accent 6"/>
  <w:LsdException Locked="false" Priority="50" Name="List Table 5 Dark Accent 6"/>
  <w:LsdException Locked="false" Priority="51"
   Name="List Table 6 Colorful Accent 6"/>
  <w:LsdException Locked="false" Priority="52"
   Name="List Table 7 Colorful Accent 6"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Mention"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Smart Hyperlink"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Hashtag"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Unresolved Mention"/>
  <w:LsdException Locked="false" SemiHidden="true" UnhideWhenUsed="true"
   Name="Smart Link"/>
 </w:LatentStyles>
</xml><![endif]-->
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-536869121 1107305727 33554432 0 415 0;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-469750017 -1073732485 9 0 511 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-parent:"";
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:8.0pt;
	margin-left:0cm;
	line-height:107%;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Calibri;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-font-kerning:1.0pt;
	mso-ligatures:standardcontextual;
	mso-fareast-language:EN-US;}
h1
	{mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Heading 1 Char";
	mso-style-next:Normal;
	margin-top:18.0pt;
	margin-right:0cm;
	margin-bottom:4.0pt;
	margin-left:0cm;
	line-height:107%;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	mso-outline-level:1;
	font-size:20.0pt;
	font-family:"Calibri Light",sans-serif;
	mso-ascii-font-family:"Calibri Light";
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:"Calibri Light";
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#2F5496;
	mso-themecolor:accent1;
	mso-themeshade:191;
	mso-font-kerning:1.0pt;
	mso-ligatures:standardcontextual;
	mso-fareast-language:EN-US;
	font-weight:normal;}
h2
	{mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-qformat:yes;
	mso-style-link:"Heading 2 Char";
	mso-style-next:Normal;
	margin-top:8.0pt;
	margin-right:0cm;
	margin-bottom:4.0pt;
	margin-left:0cm;
	line-height:107%;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	mso-outline-level:2;
	font-size:16.0pt;
	font-family:"Calibri Light",sans-serif;
	mso-ascii-font-family:"Calibri Light";
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:"Calibri Light";
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#2F5496;
	mso-themecolor:accent1;
	mso-themeshade:191;
	mso-font-kerning:1.0pt;
	mso-ligatures:standardcontextual;
	mso-fareast-language:EN-US;
	font-weight:normal;}
h3
	{mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-qformat:yes;
	mso-style-link:"Heading 3 Char";
	mso-style-next:Normal;
	margin-top:8.0pt;
	margin-right:0cm;
	margin-bottom:4.0pt;
	margin-left:0cm;
	line-height:107%;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	mso-outline-level:3;
	font-size:14.0pt;
	font-family:"Calibri",sans-serif;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#2F5496;
	mso-themecolor:accent1;
	mso-themeshade:191;
	mso-font-kerning:1.0pt;
	mso-ligatures:standardcontextual;
	mso-fareast-language:EN-US;
	font-weight:normal;}
h4
	{mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-qformat:yes;
	mso-style-link:"Heading 4 Char";
	mso-style-next:Normal;
	margin-top:4.0pt;
	margin-right:0cm;
	margin-bottom:2.0pt;
	margin-left:0cm;
	line-height:107%;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	mso-outline-level:4;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#2F5496;
	mso-themecolor:accent1;
	mso-themeshade:191;
	mso-font-kerning:1.0pt;
	mso-ligatures:standardcontextual;
	mso-fareast-language:EN-US;
	font-weight:normal;
	font-style:italic;}
h5
	{mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-qformat:yes;
	mso-style-link:"Heading 5 Char";
	mso-style-next:Normal;
	margin-top:4.0pt;
	margin-right:0cm;
	margin-bottom:2.0pt;
	margin-left:0cm;
	line-height:107%;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	mso-outline-level:5;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#2F5496;
	mso-themecolor:accent1;
	mso-themeshade:191;
	mso-font-kerning:1.0pt;
	mso-ligatures:standardcontextual;
	mso-fareast-language:EN-US;
	font-weight:normal;}
h6
	{mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-qformat:yes;
	mso-style-link:"Heading 6 Char";
	mso-style-next:Normal;
	margin-top:2.0pt;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:0cm;
	line-height:107%;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	mso-outline-level:6;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#595959;
	mso-themecolor:text1;
	mso-themetint:166;
	mso-font-kerning:1.0pt;
	mso-ligatures:standardcontextual;
	mso-fareast-language:EN-US;
	font-weight:normal;
	font-style:italic;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-qformat:yes;
	mso-style-link:"Heading 7 Char";
	mso-style-next:Normal;
	margin-top:2.0pt;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:0cm;
	line-height:107%;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	mso-outline-level:7;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#595959;
	mso-themecolor:text1;
	mso-themetint:166;
	mso-font-kerning:1.0pt;
	mso-ligatures:standardcontextual;
	mso-fareast-language:EN-US;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-qformat:yes;
	mso-style-link:"Heading 8 Char";
	mso-style-next:Normal;
	margin:0cm;
	line-height:107%;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	mso-outline-level:8;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#272727;
	mso-themecolor:text1;
	mso-themetint:216;
	mso-font-kerning:1.0pt;
	mso-ligatures:standardcontextual;
	mso-fareast-language:EN-US;
	font-style:italic;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-qformat:yes;
	mso-style-link:"Heading 9 Char";
	mso-style-next:Normal;
	margin:0cm;
	line-height:107%;
	mso-pagination:widow-orphan lines-together;
	page-break-after:avoid;
	mso-outline-level:9;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#272727;
	mso-themecolor:text1;
	mso-themetint:216;
	mso-font-kerning:1.0pt;
	mso-ligatures:standardcontextual;
	mso-fareast-language:EN-US;}
p.MsoTitle, li.MsoTitle, div.MsoTitle
	{mso-style-priority:10;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Title Char";
	mso-style-next:Normal;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:4.0pt;
	margin-left:0cm;
	mso-add-space:auto;
	mso-pagination:widow-orphan;
	font-size:28.0pt;
	font-family:"Calibri Light",sans-serif;
	mso-ascii-font-family:"Calibri Light";
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:"Calibri Light";
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	letter-spacing:-.5pt;
	mso-font-kerning:14.0pt;
	mso-ligatures:standardcontextual;
	mso-fareast-language:EN-US;}
p.MsoTitleCxSpFirst, li.MsoTitleCxSpFirst, div.MsoTitleCxSpFirst
	{mso-style-priority:10;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Title Char";
	mso-style-next:Normal;
	mso-style-type:export-only;
	margin:0cm;
	mso-add-space:auto;
	mso-pagination:widow-orphan;
	font-size:28.0pt;
	font-family:"Calibri Light",sans-serif;
	mso-ascii-font-family:"Calibri Light";
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:"Calibri Light";
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	letter-spacing:-.5pt;
	mso-font-kerning:14.0pt;
	mso-ligatures:standardcontextual;
	mso-fareast-language:EN-US;}
p.MsoTitleCxSpMiddle, li.MsoTitleCxSpMiddle, div.MsoTitleCxSpMiddle
	{mso-style-priority:10;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Title Char";
	mso-style-next:Normal;
	mso-style-type:export-only;
	margin:0cm;
	mso-add-space:auto;
	mso-pagination:widow-orphan;
	font-size:28.0pt;
	font-family:"Calibri Light",sans-serif;
	mso-ascii-font-family:"Calibri Light";
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:"Calibri Light";
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	letter-spacing:-.5pt;
	mso-font-kerning:14.0pt;
	mso-ligatures:standardcontextual;
	mso-fareast-language:EN-US;}
p.MsoTitleCxSpLast, li.MsoTitleCxSpLast, div.MsoTitleCxSpLast
	{mso-style-priority:10;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Title Char";
	mso-style-next:Normal;
	mso-style-type:export-only;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:4.0pt;
	margin-left:0cm;
	mso-add-space:auto;
	mso-pagination:widow-orphan;
	font-size:28.0pt;
	font-family:"Calibri Light",sans-serif;
	mso-ascii-font-family:"Calibri Light";
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:"Calibri Light";
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	letter-spacing:-.5pt;
	mso-font-kerning:14.0pt;
	mso-ligatures:standardcontextual;
	mso-fareast-language:EN-US;}
p.MsoSubtitle, li.MsoSubtitle, div.MsoSubtitle
	{mso-style-priority:11;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Subtitle Char";
	mso-style-next:Normal;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:8.0pt;
	margin-left:0cm;
	line-height:107%;
	mso-pagination:widow-orphan;
	font-size:14.0pt;
	font-family:"Calibri",sans-serif;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#595959;
	mso-themecolor:text1;
	mso-themetint:166;
	letter-spacing:.75pt;
	mso-font-kerning:1.0pt;
	mso-ligatures:standardcontextual;
	mso-fareast-language:EN-US;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{mso-style-priority:34;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:8.0pt;
	margin-left:36.0pt;
	mso-add-space:auto;
	line-height:107%;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Calibri;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-font-kerning:1.0pt;
	mso-ligatures:standardcontextual;
	mso-fareast-language:EN-US;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{mso-style-priority:34;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-type:export-only;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:36.0pt;
	mso-add-space:auto;
	line-height:107%;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Calibri;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-font-kerning:1.0pt;
	mso-ligatures:standardcontextual;
	mso-fareast-language:EN-US;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{mso-style-priority:34;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-type:export-only;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:36.0pt;
	mso-add-space:auto;
	line-height:107%;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Calibri;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-font-kerning:1.0pt;
	mso-ligatures:standardcontextual;
	mso-fareast-language:EN-US;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{mso-style-priority:34;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-type:export-only;
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:8.0pt;
	margin-left:36.0pt;
	mso-add-space:auto;
	line-height:107%;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Calibri;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-font-kerning:1.0pt;
	mso-ligatures:standardcontextual;
	mso-fareast-language:EN-US;}
p.MsoQuote, li.MsoQuote, div.MsoQuote
	{mso-style-priority:29;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Quote Char";
	mso-style-next:Normal;
	margin-top:8.0pt;
	margin-right:0cm;
	margin-bottom:8.0pt;
	margin-left:0cm;
	text-align:center;
	line-height:107%;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Calibri;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	color:#404040;
	mso-themecolor:text1;
	mso-themetint:191;
	mso-font-kerning:1.0pt;
	mso-ligatures:standardcontextual;
	mso-fareast-language:EN-US;
	font-style:italic;}
p.MsoIntenseQuote, li.MsoIntenseQuote, div.MsoIntenseQuote
	{mso-style-priority:30;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Intense Quote Char";
	mso-style-next:Normal;
	margin-top:18.0pt;
	margin-right:43.2pt;
	margin-bottom:18.0pt;
	margin-left:43.2pt;
	text-align:center;
	line-height:107%;
	mso-pagination:widow-orphan;
	border:none;
	mso-border-top-alt:solid #2F5496 .5pt;
	mso-border-top-themecolor:accent1;
	mso-border-top-themeshade:191;
	mso-border-bottom-alt:solid #2F5496 .5pt;
	mso-border-bottom-themecolor:accent1;
	mso-border-bottom-themeshade:191;
	padding:0cm;
	mso-padding-alt:10.0pt 0cm 10.0pt 0cm;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Calibri;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	color:#2F5496;
	mso-themecolor:accent1;
	mso-themeshade:191;
	mso-font-kerning:1.0pt;
	mso-ligatures:standardcontextual;
	mso-fareast-language:EN-US;
	font-style:italic;}
span.MsoIntenseEmphasis
	{mso-style-priority:21;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	color:#2F5496;
	mso-themecolor:accent1;
	mso-themeshade:191;
	font-style:italic;}
span.MsoIntenseReference
	{mso-style-priority:32;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	font-variant:small-caps;
	color:#2F5496;
	mso-themecolor:accent1;
	mso-themeshade:191;
	letter-spacing:.25pt;
	font-weight:bold;}
span.Heading1Char
	{mso-style-name:"Heading 1 Char";
	mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Heading 1";
	mso-ansi-font-size:20.0pt;
	mso-bidi-font-size:20.0pt;
	font-family:"Calibri Light",sans-serif;
	mso-ascii-font-family:"Calibri Light";
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:"Calibri Light";
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#2F5496;
	mso-themecolor:accent1;
	mso-themeshade:191;}
span.Heading2Char
	{mso-style-name:"Heading 2 Char";
	mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Heading 2";
	mso-ansi-font-size:16.0pt;
	mso-bidi-font-size:16.0pt;
	font-family:"Calibri Light",sans-serif;
	mso-ascii-font-family:"Calibri Light";
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:"Calibri Light";
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#2F5496;
	mso-themecolor:accent1;
	mso-themeshade:191;}
span.Heading3Char
	{mso-style-name:"Heading 3 Char";
	mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Heading 3";
	mso-ansi-font-size:14.0pt;
	mso-bidi-font-size:14.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#2F5496;
	mso-themecolor:accent1;
	mso-themeshade:191;}
span.Heading4Char
	{mso-style-name:"Heading 4 Char";
	mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Heading 4";
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#2F5496;
	mso-themecolor:accent1;
	mso-themeshade:191;
	font-style:italic;}
span.Heading5Char
	{mso-style-name:"Heading 5 Char";
	mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Heading 5";
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#2F5496;
	mso-themecolor:accent1;
	mso-themeshade:191;}
span.Heading6Char
	{mso-style-name:"Heading 6 Char";
	mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Heading 6";
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#595959;
	mso-themecolor:text1;
	mso-themetint:166;
	font-style:italic;}
span.Heading7Char
	{mso-style-name:"Heading 7 Char";
	mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Heading 7";
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#595959;
	mso-themecolor:text1;
	mso-themetint:166;}
span.Heading8Char
	{mso-style-name:"Heading 8 Char";
	mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Heading 8";
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#272727;
	mso-themecolor:text1;
	mso-themetint:216;
	font-style:italic;}
span.Heading9Char
	{mso-style-name:"Heading 9 Char";
	mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Heading 9";
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#272727;
	mso-themecolor:text1;
	mso-themetint:216;}
span.TitleChar
	{mso-style-name:"Title Char";
	mso-style-priority:10;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:Title;
	mso-ansi-font-size:28.0pt;
	mso-bidi-font-size:28.0pt;
	font-family:"Calibri Light",sans-serif;
	mso-ascii-font-family:"Calibri Light";
	mso-ascii-theme-font:major-latin;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-hansi-font-family:"Calibri Light";
	mso-hansi-theme-font:major-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	letter-spacing:-.5pt;
	mso-font-kerning:14.0pt;}
span.SubtitleChar
	{mso-style-name:"Subtitle Char";
	mso-style-priority:11;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:Subtitle;
	mso-ansi-font-size:14.0pt;
	mso-bidi-font-size:14.0pt;
	font-family:"Times New Roman",serif;
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:major-fareast;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:major-bidi;
	color:#595959;
	mso-themecolor:text1;
	mso-themetint:166;
	letter-spacing:.75pt;}
span.QuoteChar
	{mso-style-name:"Quote Char";
	mso-style-priority:29;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:Quote;
	color:#404040;
	mso-themecolor:text1;
	mso-themetint:191;
	font-style:italic;}
span.IntenseQuoteChar
	{mso-style-name:"Intense Quote Char";
	mso-style-priority:30;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Intense Quote";
	color:#2F5496;
	mso-themecolor:accent1;
	mso-themeshade:191;
	font-style:italic;}
span.SpellE
	{mso-style-name:"";
	mso-spl-e:yes;}
span.GramE
	{mso-style-name:"";
	mso-gram-e:yes;}
.MsoChpDefault
	{mso-style-type:export-only;
	mso-default-props:yes;
	font-size:11.0pt;
	mso-ansi-font-size:11.0pt;
	mso-bidi-font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-fareast-font-family:Calibri;
	mso-fareast-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-fareast-language:EN-US;}
.MsoPapDefault
	{mso-style-type:export-only;
	margin-bottom:8.0pt;
	line-height:107%;}
@page WordSection1
	{size:595.3pt 841.9pt;
	margin:72.0pt 72.0pt 72.0pt 72.0pt;
	mso-header-margin:35.4pt;
	mso-footer-margin:35.4pt;
	mso-paper-source:0;}
div.WordSection1
	{page:WordSection1;}
-->
</style>
<!--[if gte mso 10]>
<style>
 /* Style Definitions */
 table.MsoNormalTable
	{mso-style-name:"Table Normal";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-parent:"";
	mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
	mso-para-margin-top:0cm;
	mso-para-margin-right:0cm;
	mso-para-margin-bottom:8.0pt;
	mso-para-margin-left:0cm;
	line-height:107%;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;
	mso-ascii-font-family:Calibri;
	mso-ascii-theme-font:minor-latin;
	mso-hansi-font-family:Calibri;
	mso-hansi-theme-font:minor-latin;
	mso-bidi-font-family:"Times New Roman";
	mso-bidi-theme-font:minor-bidi;
	mso-font-kerning:1.0pt;
	mso-ligatures:standardcontextual;
	mso-fareast-language:EN-US;}
</style>
<![endif]--><!--[if gte mso 9]><xml>
 <o:shapedefaults v:ext="edit" spidmax="1026"/>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <o:shapelayout v:ext="edit">
  <o:idmap v:ext="edit" data="1"/>
 </o:shapelayout></xml><![endif]-->
</head>

<body lang=EN-GB style='tab-interval:36.0pt;word-wrap:break-word'>

<div class=WordSection1>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

<p class=MsoNormal>A systematic review of the evidence for the clinical
effectiveness and safety of etanercept, infliximab and adalimumab for the
treatment of active and progressive PsA in patients who have an inadequate
response to standard treatment (including DMARD therapy) was conducted
following the general principles recommended in the guidance of the Centre for
Reviews and Dissemination (CRD) guidance75 and the quality of reporting of
meta-analyses (QUOROM) statement.76<o:p></o:p></p>

<p class=MsoNormal>Search strategy<o:p></o:p></p>

<p class=MsoNormal>The following databases were searched for relevant clinical
effectiveness and cost-effectiveness research:<o:p></o:p></p>

<p class=MsoNormal>&#61607;<span style='mso-tab-count:1'> </span>MEDLINE<o:p></o:p></p>

<p class=MsoNormal>&#61607;<span style='mso-tab-count:1'> </span>EMBASE<o:p></o:p></p>

<p class=MsoNormal>&#61607;<span style='mso-tab-count:1'> </span>Cochrane
Central Register of Controlled Trials (CENTRAL)<o:p></o:p></p>

<p class=MsoNormal>&#61607;<span style='mso-tab-count:1'> </span>Science
Citation Index (SCI)<o:p></o:p></p>

<p class=MsoNormal>&#61607;<span style='mso-tab-count:1'> </span>Conference
Proceedings Citation Index  Science (CPCI-S)<o:p></o:p></p>

<p class=MsoNormal>&#61607;<span style='mso-tab-count:1'> </span>ClinicalTrials.gov<o:p></o:p></p>

<p class=MsoNormal>&#61607;<span style='mso-tab-count:1'> </span><span
class=SpellE>metaRegister</span> of Current Controlled Trials (<span
class=SpellE>mRCT</span>)<o:p></o:p></p>

<p class=MsoNormal>&#61607;<span style='mso-tab-count:1'> </span>NHS
Economic Evaluation Database (NHS EED)<o:p></o:p></p>

<p class=MsoNormal>&#61607;<span style='mso-tab-count:1'> </span>Health
Economic Evaluations Database (HEED)<o:p></o:p></p>

<p class=MsoNormal>&#61607;<span style='mso-tab-count:1'> </span><span
class=SpellE>EconLit</span>.<o:p></o:p></p>

<p class=MsoNormal>Searches of major bibliographic databases were undertaken in
three tranches  for RCTs, for economic evaluations and for studies of serious
adverse effects. In the RCT and economic evaluation searches, the etanercept
and infliximab search was limited by date (1 April 2004 to date), updating the
searches undertaken for the 2006 Health Technology Assessment (HTA) report.73
The search for adalimumab had no date limits. The searches for studies of
adverse effects of all three drugs were not date limited. Internet resources
were also searched for information on adverse effects. At the time of receiving
the company submission (August 2009), update searches were conducted to ensure
that the review remained up to date and covered all relevant evidence at the
time of submission. No language or other restrictions were applied. In
addition, reference lists of all included studies and industry submissions made
to NICE were hand-searched to identify further relevant studies.<o:p></o:p></p>

<p class=MsoNormal>The terms for search strategies were identified through
discussion between an information specialist and the research team, by scanning
the background literature and browsing the MEDLINE medical subject headings (<span
class=SpellE>MeSH</span>). As several databases were searched, some degree of
duplication resulted. To manage this issue, the titles and abstracts of
bibliographic records were imported into endnote bibliographic management
software to remove duplicate records.<o:p></o:p></p>

<p class=MsoNormal>Inclusion and exclusion criteria<o:p></o:p></p>

<p class=MsoNormal>Two reviewers independently screened all titles and
abstracts. Full paper manuscripts of any titles/abstracts that may be relevant
were obtained where possible and the relevance of each study was assessed by
two reviewers according to the criteria below. Studies were included in the
review according to the inclusion criteria, described as follows. Studies that
did not meet <span class=GramE>all of</span> the criteria were excluded and
their bibliographic details listed with reasons for exclusion. Any
discrepancies were resolved by consensus or consulting a third reviewer if
necessary.<o:p></o:p></p>

<p class=MsoNormal>Study design<o:p></o:p></p>

<p class=MsoNormal>Randomised controlled trials (including any open-label
extensions of these RCTs) were included in the evaluation of efficacy.
Information on the rate of serious adverse events was sought from regulatory
sources [the US Food and Drug Administration (FDA), European Medicines Agency
(EMEA)]. If these failed to report the necessary data to calculate event rates
then non-randomised studies that provided these data for etanercept, infliximab
and adalimumab were included in the review. If multiple non-randomised studies
were identified, inclusion was limited to those studies reporting outcomes for
a minimum of 500 patients receiving biologic therapy.<o:p></o:p></p>

<p class=MsoNormal>Interventions<o:p></o:p></p>

<p class=MsoNormal>Etanercept, infliximab and adalimumab were the interventions
of interest. Comparators were placebo, another of the three listed agents, or
conventional management strategies for active and progressive PsA that have
responded inadequately to previous DMARD therapy, excluding TNF inhibitors.<o:p></o:p></p>

<p class=MsoNormal>Participants<o:p></o:p></p>

<p class=MsoNormal>For the evaluation of the effectiveness of etanercept,
infliximab and adalimumab, included studies were of adults with active and
progressive PsA with an inadequate response to previous standard therapy
(including at least one DMARD). Trials of effectiveness had to specify that the
patients had PsA, with the definition and/or the inclusion criteria for PsA
stated. For the assessment of adverse effects, studies of patients with other
conditions were eligible for inclusion in the review.<o:p></o:p></p>

<p class=MsoNormal>Outcomes<o:p></o:p></p>

<p class=MsoNormal>The eligible outcomes of effectiveness were measures of the
anti-inflammatory response (<span class=SpellE>PsARC</span>, ACR 20/50/70),
response of psoriatic skin lesions (PASI), functional measures (HAQ),
radiological assessments of disease progression or remission, QoL assessments
[e.g. Dermatology Life Quality Index (DLQI)] and overall global assessments.<o:p></o:p></p>

<p class=MsoNormal>In terms of the outcomes of adverse events of biologics, we
provided an initial overview of previous systematic reviews of biologic safety
(see Results of review of clinical effectiveness) before conducting our
systematic review of adverse events of these agents. Our systematic review
specifically focused on the known serious adverse events of these agents:
malignancies, severe infections (i.e. those that require <span class=SpellE>i.v.</span>
antibiotic therapy and/or hospitalisation or cause death) and reactivation of
latent tuberculosis (TB). If additional serious adverse events have been
reported to regulatory <span class=GramE>bodies</span> then the incidence of
these were also assessed. In addition, data relating to serious adverse events
in indications other than PsA were also considered in our systematic review,
provided it was clinically appropriate to do so.<o:p></o:p></p>

<p class=MsoNormal>Data extraction strategy<o:p></o:p></p>

<p class=MsoNormal>Data on study and participant characteristics, efficacy
outcomes, adverse effects, costs to the health service and cost-effectiveness
were extracted. Baseline data were extracted where reported. Data were
extracted by one reviewer using a standardised data extraction form and
independently checked for accuracy by a second reviewer. The results of data
extraction were presented in the structured tables (see Appendix 3, Efficacy
data extraction: etanercept/infliximab/adalimumab). Disagreements were resolved
through <span class=GramE>consensus, or</span> consulting a third reviewer if
necessary. Attempts were made, where possible, to contact authors for missing
data. Data from studies with multiple publications were extracted and reported
as a single study. In the rare case of minor discrepancies for the same data
between published and unpublished data, data from published sources were used.<o:p></o:p></p>

<p class=MsoNormal>Quality assessment strategy<o:p></o:p></p>

<p class=MsoNormal>The quality of RCTs and other study designs were assessed
using standard checklists.75 Regarding the additional studies reviewed for data
on serious adverse events: as all observational studies are prone to
confounding and bias to some extent, non-randomised studies including &lt; 500
patients receiving biologics were excluded from the review. The assessment was
performed by one reviewer and checked independently by a second. Disagreements
were resolved through consensus or by consulting a third reviewer if necessary.<o:p></o:p></p>

<p class=MsoNormal>Data analysis<o:p></o:p></p>

<p class=MsoNormal>Where sufficient clinically and statistically homogeneous
data were available, data were pooled using standard meta-analytic methods. The
levels of clinical and methodological heterogeneity were investigated, and
statistical heterogeneity was assessed using Q- and I2-statistics. Given the
small number of trials available, a fixed-effects model was used to pool
outcomes where pooling was appropriate. Sensitivity analyses were undertaken
when permitted by sufficient data (e.g. exclusion of concomitant MTX treatment).
The potential short- and long-term benefits of etanercept, infliximab and
adalimumab on both the psoriasis and arthritis components of PsA were
investigated. The rates of serious adverse effects of these biologic agents
were synthesised narratively.<o:p></o:p></p>

<p class=MsoNormal>As trials conducting head-to-head comparisons of etanercept,
infliximab and adalimumab were not available the possibility of conducting some
form of indirect comparison was investigated. Indirect comparisons are useful
analytic tools when direct evidence on comparisons of interest is absent or
sparse.77 Meta-analysis using indirect comparisons enables data from several
sources to be combined, while <span class=GramE>taking into account</span>
differences between the different sources, in a similar way to, but distinct
from, how a random-effects model takes into account between-trial
heterogeneity. As with a mixed-treatment comparison (MTC), Bayesian indirect
comparisons need a network of evidence to be established between <span
class=GramE>all of</span> the interventions of interest. The three drugs being
evaluated all have a common comparator: placebo. It is this common comparator
that allows the network between etanercept, infliximab and adalimumab to be
established and provide information on the benefits of these agents relative to
placebo and each other.<o:p></o:p></p>

<p class=MsoNormal>To help inform both the clinical review and the economic
modelling four separate outcomes were considered. These outcomes were: <span
class=SpellE>PsARC</span> response, HAQ score conditional on <span
class=SpellE>PsARC</span> response, ACR 20/50/70 responses and PASI 50/75/90
responses. All outcomes were evaluated at 12 weeks. The evidence synthesis was
undertaken using <span class=SpellE>winbugs</span> (version 1.4.2). <span
class=SpellE>winbugs</span> is a Bayesian analysis software tool that, <span
class=GramE>through the use of</span> Markov chain Monte Carlo, calculates
posterior distributions for the parameters of interest given likelihood
functions derived from data and prior probabilities. Full details of the
Bayesian indirect comparison methods and the <span class=SpellE>winbugs</span>
codes along for the four different analyses are presented in Appendix 5.<o:p></o:p></p>

<p class=MsoNormal>Go to:<o:p></o:p></p>

<p class=MsoNormal>Results of review of clinical effectiveness<o:p></o:p></p>

<p class=MsoNormal>Quantity and quality of research available<o:p></o:p></p>

<p class=MsoNormal>A total of 1320 records were identified from both the
clinical effectiveness and adverse event searches (Figure 1). Details of
studies excluded at the full publication stage are provided in Appendix 4.<o:p></o:p></p>

<p class=MsoNormal>Etanercept, Infliximab and Adalimumab for the Treatment of
Psoriatic Arthritis: A Systematic Review and Economic Evaluation.<o:p></o:p></p>

<p class=MsoNormal>Show details<o:p></o:p></p>

<p class=MsoNormal>Health Technology Assessment, No. 15.10.<o:p></o:p></p>

<p class=MsoNormal>Rodgers M, Epstein D, <span class=SpellE>Bojke</span> L, et
al.<o:p></o:p></p>

<p class=MsoNormal>Southampton (UK): NIHR Journals Library; 2011 Feb.<o:p></o:p></p>

<p class=MsoNormal><span style='mso-tab-count:1'> </span>Contents<o:p></o:p></p>

<p class=MsoNormal>Search term<o:p></o:p></p>

<p class=MsoNormal><span style='mso-spacerun:yes'></span><o:p></o:p></p>

<p class=MsoNormal><span style='mso-spacerun:yes'></span><o:p></o:p></p>

<p class=MsoNormal>&lt; <span class=SpellE>PrevNext</span> &gt;<o:p></o:p></p>

<p class=MsoNormal>4Assessment of cost-effectiveness evidence<o:p></o:p></p>

<p class=MsoNormal>Go to:<o:p></o:p></p>

<p class=MsoNormal>Systematic review of existing cost-effectiveness evidence<o:p></o:p></p>

<p class=MsoNormal>The purpose of this section of the report is to review
existing evidence on the cost-effectiveness of biologic therapy in <span
class=SpellE>PsA.</span> It includes submissions made to NICE by the
manufacturers of the three biologic agents included in this assessment.<o:p></o:p></p>

<p class=MsoNormal>Methods<o:p></o:p></p>

<p class=MsoNormal>A broad range of studies was considered for inclusion in the
assessment of cost-effectiveness, including economic evaluations conducted
alongside trials and modelling studies. Only full economic evaluations that
compared two or more options, and considered both costs and consequences, were
included.<o:p></o:p></p>

<p class=MsoNormal>The following databases were searched for relevant published
literature: Cochrane Controlled Trials Register (CCTR), EMBASE, HEED, MEDLINE,
National Research Register (NRR), NHS EED, PsycINFO and SCI. Full details of
the main search strategy for this review are presented in Appendix 1.<o:p></o:p></p>

<p class=MsoNormal>Two reviewers assessed all obtained titles and abstracts for
inclusion, with any discrepancies resolved by discussion. In addition, the
industry submissions to NICE were included in the review.<o:p></o:p></p>

<p class=MsoNormal>The studies have been summarised within the text of the
report. A summary of effectiveness, costs and cost-effectiveness is presented
along with a critique of the studies. The quality of the cost-effectiveness
studies was also assessed according to a checklist updated from that developed
by Drummond et al.175<o:p></o:p></p>

<p class=MsoNormal>Results<o:p></o:p></p>

<p class=MsoNormal>Identified studies<o:p></o:p></p>

<p class=MsoNormal>The systematic literature of published literature identified
three studies,176178 which met the inclusion criteria for the
cost-effectiveness review (one of which is the journal publication of the
previous York Assessment Report model for NICE on etanercept and infliximab73).
In <span class=GramE>addition</span> there were three industry submissions to
NICE from Abbott,151 Schering-Plough152 and Wyeth.153<o:p></o:p></p>

<p class=MsoNormal>Of the six cost-effectiveness studies available, described
above, five of these are decision-analytic models, incorporating evidence from
a variety of sources, and one is a cost-effectiveness study, using evidence
from a single trial.<o:p></o:p></p>

<p class=MsoNormal>Available data<o:p></o:p></p>

<p class=MsoNormal>Table 31 summarises the data available from each of the six
cost-effectiveness studies.151153,176178 The studies by Olivieri et al.178
and <span class=SpellE>Bansback</span> et al.176 are only available as journal
articles. The study by Bravo Vergel et al.177 is available as a journal
article, but also as a full assessment report with an accompanying electronic
model.73 The three industry submissions included full reports and electronic
models. Where an electronic model has been made available it has been possible
to provide some validation of the model by ensuring that the base-case results
provided by the manufacturer in its report can be replicated. It was also
possible to check parameter estimates presented in the reports against those
used in the relevant models.<o:p></o:p></p>

<p class=MsoNormal><span style='mso-spacerun:yes'></span><o:p></o:p></p>

<p class=MsoNormal>TABLE 31<o:p></o:p></p>

<p class=MsoNormal>Summary of information sources available for the
cost-effectiveness studies.<o:p></o:p></p>

<p class=MsoNormal>Due to differences in the regression methods used to
generate utility estimates in the industry submissions, the Assessment Group
requested that each manufacturer provide new utility estimates using a common
methodology (see Appendix 17) and report the results of this regression, as
coefficients, a variancecovariance matrix, the number of observations, the
number of clusters (if appropriate) and indicating the source of data. This
information was provided by manufacturers for all three of the submissions.<o:p></o:p></p>

<p class=MsoNormal>In addition, <span class=GramE>a number of</span> further
clarifications on data sources and methodology were sought from the three
manufacturers on data sources and methodology (full details in Appendix 6).
Wyeth153 clarified that 12- and 24-week response rates were modelled
independently, provided an estimation of HAQ without PASI as a predictor, and
clarified how withdrawal rates were calculated (see Critique of manufacturers'
submissions and justification for current York modelling approach). Abbott151
clarified how many DMARDs were sequenced in the model, how withdrawal rates
were calculated (see Chapter 4, Critique) and clarified the degree of
correlation between arthritis and skin outcomes. No further clarifications were
sought from Schering-Plough152 other than the additional utility regressions.<o:p></o:p></p>

<p class=MsoNormal>Summaries of cost-effectiveness studies<o:p></o:p></p>

<p class=MsoNormal>A full description of each of the six cost-effectiveness
studies, along with a quality assessment checklist, is presented in Appendix 7.
Table 32 summarises the key features and data sources for each of the studies.<o:p></o:p></p>

<p class=MsoNormal><span style='mso-spacerun:yes'></span><o:p></o:p></p>

<p class=MsoNormal>TABLE 32<o:p></o:p></p>

<p class=MsoNormal>Summary of cost-effectiveness evidence identified in the
review.<o:p></o:p></p>

<p class=MsoNormal>As shown in Table 32, the six cost-effectiveness studies
produce different costs and quality-adjusted life-years (QALYs), resulting in
different incremental cost-effectiveness ratios (ICERs) for the various options
being compared. The study by Olivieri et al.178 is difficult to compare with
the others, as all biologics were considered as a group compared with DMARDs.
This produced an ICER of around 40,000 for biologics. <span class=SpellE>Bansback</span>
et al.176 produced an ICER of around 38,000 for etanercept compared with the next
best strategy  leflunomide. Bravo Vergel et al.177 produced a much lower ICER
for etanercept, of between 26,361 and 30,628, depending on the rebound
scenario used. The studies including all three biologics in this assessment 
adalimumab, etanercept and infliximab  also show large differences in results.
Abbott151 generates an ICER for adalimumab of 29,827, with etanercept
dominated by adalimumab and infliximab, with an ICER over 199,000.
Schering-Plough152 report results for all patients, psoriatic patients and
non-psoriatic patients. For all patients, etanercept is the most cost-effective
strategy, assuming a patient weight of 70 or 80 kg (ICER of 12,606 compared
with adalimumab). For a 60-kg patient etanercept is the most cost-effective
strategy for patients without psoriasis (ICER of 12,432 compared with
adalimumab) and infliximab is the most cost-effective for psoriatic patients
and all patients, dominating etanercept. Wyeth153 produces a base-case ICER for
etanercept of 12,480 compared with DMARDs. All other biologics are dominated
or extendedly dominated.<o:p></o:p></p>

<p class=MsoNormal>It is difficult to disentangle exactly why, in some cases,
the six studies produce markedly different results. However, there are <span
class=GramE>a number of</span> key differences between the modelling approaches
and the data sources used in the six cost-effectiveness studies that may
provide some explanation.<o:p></o:p></p>

<p class=MsoNormal>1.<span style='mso-tab-count:1'> </span>Choice of
comparator All biologics were grouped together in the Olivieri et al. study,178
although <span class=GramE>the majority of</span> patients were taking
etanercept. It is, therefore, not possible to estimate any differences in the
cost-effectiveness between the biological agents. <span class=SpellE>Bansback</span>
et al.176 compare only etanercept with DMARDs, omitting all other biologics,
whereas Bravo Vergel et al.177 compare only infliximab and etanercept with
palliative care. The models from Abbott,151 Schering-Plough152 and Wyeth153 all
include the three biologics etanercept, infliximab and adalimumab. However,
Abbott151 and Wyeth153 compare these with DMARDs, whereas Schering-Plough152
use palliative care as the comparator. The patient group specified by the
decision problem (see Executive summary, Objectives) are those who have
previously failed two DMARDs. Therefore, these patients may be unlikely to be
considered for further DMARD treatment, which suggests that they would instead
receive palliative care.<o:p></o:p></p>

<p class=MsoNormal>2.<span style='mso-tab-count:1'> </span>Sources
and synthesis of effectiveness data Olivieri et al.178 use a relatively small
sample of patients recruited from a single site. The analysis has a limited
length of follow-up (12 months) and, as PsA is a chronic disease, it is
unlikely that all differences in costs and outcomes between comparators can be
captured in this short time frame. This is also a before/after study, so there
may be a problem of selection bias. <span class=SpellE>Bansback</span> et
al.176 similarly use data from a <span class=GramE>single phase II</span> trial
to determine effectiveness. Other relevant randomised trials are now available,
and this evidence should be appropriately synthesised to inform
cost-effectiveness. The models by Bravo Vergel et al.,177 Abbott,151
Schering-Plough152 and Wyeth153 all use multiple sources to determine the
short-term effectiveness of treatments, all of these synthesising data using a <span
class=GramE>Bayesian methods</span> in <span class=SpellE>winbugs</span>.
However, in the Abbott151 and Schering-Plough152 models, some of these data
sources relate to treatments not included as comparators in the model, such as
golimumab (see Chapter 3, Results of review of clinical effectiveness). The
implications of using this wider selection of treatments in the evidence synthesis
are uncertain.<o:p></o:p></p>

<p class=MsoNormal>3.<span style='mso-tab-count:1'> </span>Effect of
treatment on skin component of disease Although PsA is associated with
psoriasis as well as an inflammation of the joints, <span class=SpellE>Bansback</span>
et al.176 and Bravo Vergel et al.177 do not include the effect of treatments on
the skin component of PsA, whereas the models by Abbott,151 Wyeth153 and
Schering-Plough152 all include the effect of both conditions. In the Wyeth
model,153 however, the initial change and longer-term changes in HAQ were
determined, including PASI as an explanatory variable. Although PASI and HAQ
are used to measure the severity of the two components of PsA, psoriasis and
arthritis, there are only limited circumstances in which a patient's psoriasis
should affect their degree of functional disability or joint disease, as
measured by HAQ.<o:p></o:p></p>

<p class=MsoNormal>4.<span style='mso-tab-count:1'> </span>Model
structure Olivieri et al.178 does not use a model to generate estimates of
costs and QALYs and instead uses the results of an economic evaluation
conducted alongside a single trial. The models by <span class=SpellE>Bansback</span>
et al.,176 Bravo Vergel et al.177 and Schering-Plough152 all determine response
according to <span class=SpellE>PsARC</span> and then model the associated HAQ
score. Schering-Plough152 includes PASI change from baseline to 12 <span
class=GramE>weeks, but</span> estimates this for weeks for <span class=SpellE>PsARC</span>
responders/non-responders. Wyeth153 similarly determines response according to <span
class=SpellE>PsARC</span> and calculates the associated change in HAQ and PASI.
However, initial change in HAQ is modelled using changes in PASI and <span
class=SpellE>PsARC</span>, and longer-term changes in HAQ were modelled using
observed changes in PASI score, PASI 75 response and <span class=SpellE>PsARC</span>
response. Abbott151 use ACR response rates in addition to <span class=SpellE>PsARC</span>
to determine the joint distribution of response, and then associated HAQ and
PASI changes by type of response. Schering-Plough152 assumes that changes in
HAQ in the first 3 months are a function of <span class=SpellE>PsARC</span>
response and the biologic used, whereas Abbott151 and Wyeth153 assume that
changes in HAQ are independent of the biologic used after conditioning on other
predictive clinical and demographic variables (such as ACR and age).<o:p></o:p></p>

<p class=MsoNormal>5.<span style='mso-tab-count:1'> </span>Patient
characteristics <span class=GramE>Of</span> the five model-based studies, three
of these use an individual sampling approach, with baseline characteristics
taken from IPD from trials.151,153,176 Bravo Vergel et al.177 and
Schering-Plough152 both use cohort models, with common baseline HAQ/PASI scores,
which are then varied in a sensitivity analysis. The individual sampling models
are complex and time intensive <span class=GramE>in order to</span> run
probabilistic sensitivity analysis. They are also difficult to audit and there
may be differences in methodology used in these models that the Assessment
Group were not able to fully explain in the constrained timescale.<o:p></o:p></p>

<p class=MsoNormal>6.<span style='mso-tab-count:1'> </span>Sources of
cost data <span class=GramE>In</span> their trial-based evaluation, Olivieri et
al.178 collected resource use data retrospectively from patients and valued
these using appropriate unit costs. The model-based studies all include the
same set of costs: drug acquisition, drug administration and monitoring, and
costs of disability and psoriasis (where PASI was included in the model).
However, the cost estimates generated differ quite significantly between models
(see Critique of manufacturers' submissions and justification for current York
modelling approach), reflecting different methodology and sources of data.<o:p></o:p></p>

<p class=MsoNormal>7.<span style='mso-tab-count:1'> </span>Sources of
utility data Olivieri et al.178 collected utilities directly from patients who
were enrolled in the trial, using the European Quality of Life-5 Dimensions
(EQ-5D questionnaire). These were collected for the 6 months preceding biologic
treatment, baseline, and 6 months and 12 months after starting treatment. The
other studies use different external data sets to generate utilities and used
regression analysis to link the utility data to clinical parameters. Each of
the studies assumed that utility was independent of the biologic treatment
used, after conditioning on HAQ and PASI. However, each used a different
function to relate utility to HAQ and PASI, and it is possible that different
utility regressions result in differences in the relative impact of HAQ/PASI on
utility between treatments. <span class=SpellE>Bansback</span> et al.176 and
Bravo Vergel et al.177 both use the Leeds cohort study as a source of utility
estimates. Abbott151 use the ADEPT trial88 of adalimumab, which reports Short
Form questionnaire-36 items (SF-36 data), which are then converted to EQ-5D to
generate utilities. Schering-Plough152 use the same <span class=GramE>approach,
but</span> use the GO-REVEAL (Golimumab-Randomized Evaluation of Safety and
Efficacy in Subjects with Psoriatic Arthritis Using a Human Anti-TNF Monoclonal
Antibody)156 trial data set. Wyeth153 use the relationship between HAQ and
EQ-5D observed in the Psoriasis Randomized Etanercept <span class=SpellE>STudy</span>
in Subjects with Psoriatic Arthritis (PRESTA) data set in the base case to
generate utilities, and the relationship between PASI and EQ-5D was indirectly
included only through the effect of PASI on HAQ.<o:p></o:p></p>

<p class=MsoNormal>Relevance of cost-effectiveness evidence for NICE
decision-making<o:p></o:p></p>

<p class=MsoNormal>The evidence provided from the cost-effectiveness study
conducted alongside a single trial178 is not considered relevant for UK
decision-making because of its lack of a concurrent control group, narrow use
of evidence (a single trial) and limited length of follow-up (12 months). The
five modelling studies are, however, potentially relevant for UK
decision-making. The current appraisal has recognised the need to assess the
effect of biologics on both the arthritis and the psoriasis component of the
disease. Only the three industry models include the psoriasis aspect of PsA,
and therefore only these models are relevant to address the decision problem as
specified by the NICE scope.<o:p></o:p></p>

<p class=MsoNormal>There are <span class=GramE>a number of</span> issues with
the three industry models that require further consideration. These are
discussed in further detail in the section Critique of manufacturers'
submissions and justification for current York modelling approach, later in
this chapter, but can be summarised as:<o:p></o:p></p>

<p class=MsoNormal>&#61607;<span style='mso-tab-count:1'> </span>The
use of DMARDs as a comparator to biologics used in the Wyeth153 and Abbott151
models. This approach can be criticised if it is considered unrealistic for
patients who have previously failed two or more DMARDs, as defined in the BSR
guidelines149 to receive a third DMARD.<o:p></o:p></p>

<p class=MsoNormal>&#61607;<span style='mso-tab-count:1'> </span>In
estimating the treatment effect, the Abbott151 and Schering-Plough152 models
use data sources relating to comparators not included in the model, such as
golimumab, and the implications of this are not clear. It is uncertain whether
the relative treatment effects can be transferred from one biologic to another.<o:p></o:p></p>

<p class=MsoNormal>&#61607;<span style='mso-tab-count:1'> </span><span
class=GramE>Also</span> for the Wyeth submission153 data from an existing
synthesis for adalimumab179 and the Mease et al. trial52 were used to estimate
effects. Although data were included from a number of trials in the adalimumab
MTC, new trial evidence may be <span class=GramE>available</span> and efforts
should be made to identify any new relevant data.<o:p></o:p></p>

<p class=MsoNormal>&#61607;<span style='mso-tab-count:1'> </span>In
estimating the treatment effect, it is also important to consider what
treatment effect is likely to be observed in general practice. RCTs might
overestimate the absolute response rates in both placebo and treatment groups.
Schering-Plough152 assume that this is the case and adjust the expected
effectiveness of biologics, whereas the Wyeth153 and Abbott151 models do not
make any such adjustment. The models do not use sensitivity analysis to assess
how much difference this adjustment makes to the results.<o:p></o:p></p>

<p class=MsoNormal>&#61607;<span style='mso-tab-count:1'> </span>Withdrawals
after 3 months due to adverse events and lack of efficacy were estimated from a
single data set (BSR register) in <span class=GramE>all of</span> the industry
models. There <span class=GramE>are</span> other potential biologic registry
data sets available, which could have been synthesised.<o:p></o:p></p>

<p class=MsoNormal>&#61607;<span style='mso-tab-count:1'> </span>The
prediction of initial change in HAQ and longer-term changes in HAQ using PASI
as an explanatory variable in the Wyeth model153 is questionable. There is no
evidence to suggest that one component of the disease is a good predictor of
the other, although there may be a correlation between joint and skin response,
which has not been explored in any detail by the industry models.<o:p></o:p></p>

<p class=MsoNormal>&#61607;<span style='mso-tab-count:1'> </span>There
are some considerable differences in the sources of costs and the costing
methodology used in each of the three industry models (see Critique of
manufacturers' submissions and justification for current York modelling
approach). It is therefore important to understand what these differences are
and to generate appropriate costs for the model.<o:p></o:p></p>

<p class=MsoNormal>&#61607;<span style='mso-tab-count:1'> </span>The
results from each of the industry models are also markedly different. There is
therefore a need to develop a de novo model that considers and addresses each
of these limitations. This model is presented below.<o:p></o:p></p>

<p class=MsoNormal>Go to:<o:p></o:p></p>

<p class=MsoNormal>York Economic Assessment<o:p></o:p></p>

<p class=MsoNormal>Methods of York Economic Assessment<o:p></o:p></p>

<p class=MsoNormal>Introduction<o:p></o:p></p>

<p class=MsoNormal>The review of models detailed in published literature
(including the earlier one by the York Assessment Group) and those in the
company submissions to this appraisal (see Systematic review of existing
cost-effectiveness evidence) indicates that a wide range of assumptions and
evidence was used in model development. None of the models reviewed can be
considered unequivocally superior to the others. In this section we further
develop the earlier York Assessment Group model, reflecting more recent
evidence about PsA and the use of biologics in its treatment. This model also
provides a framework within which to compare the assumptions and evidence used
in the different models and to assess their implications for the
cost-effectiveness results.<o:p></o:p></p>

<p class=MsoNormal>Previous guidance has been issued by NICE on the use of
biologics in PsA.182,183 The main limitation of the economic assessments
informing this earlier guidance was that they did not take account of the
effect of the drugs on psoriasis. Therefore, a key objective of the updated
York model is to assess the cost-effectiveness of etanercept, infliximab and
adalimumab for PsA, taking account of the cost and health impact of the
patient's psoriasis and joint disease, and the impact of therapy.<o:p></o:p></p>

<p class=MsoNormal>Methods<o:p></o:p></p>

<p class=MsoNormal>Overview<o:p></o:p></p>

<p class=MsoNormal>A probabilistic decision-analytic model was developed to
estimate the costs and QALYs of the three biologics over a lifetime (40 years)
compared with palliative care only. The model has similarities with the earlier
York Assessment Group model, but <span class=GramE>a number of</span> changes
have been implemented, necessitating a full description of the model here. The
model aims to be consistent with licensed indications and current BSR149 and
BAD173 guidelines for the use of biologics in PsA (Box 1).<o:p></o:p></p>

<p class=MsoNormal><span style='mso-spacerun:yes'></span><o:p></o:p></p>

<p class=MsoNormal>BOX 1<o:p></o:p></p>

<p class=MsoNormal>Licensed indications and guidelines for commencing biologics
in <span class=SpellE>PsA.</span> Etanercept, infliximab and adalimumab are
licensed for the treatment of active and progressive PsA in adults when the
response of previous DMARD therapy has been inadequate. Infliximab (more...)<o:p></o:p></p>

<p class=MsoNormal>The parameters of the model were obtained from published
literature, manufacturers' parameter estimates, the results of the evidence
synthesis in Chapter 3, Efficacy of all three biologics and a structured
elicitation of expert opinion. The model adopts the perspective of the UK NHS
and Personal Social Services. The price year is 20089 and the annual discount
rate is 3.5%.184 The population is assumed to be 47 years old, with at least 7
years since diagnosis of PsA, based on the average characteristics of participants
in the RCTs (see Table 1). The body weight is assumed to be between 60 and 80
kg, based on the mean adult weight in the UK general population (women 69.7 kg,
men 83.5 kg185). Patients are assumed to have failed at least two DMARDs. In
the base case, patients are assumed to fulfil BSR criteria (see Box 1). In the
base case the HAQ at the start of the model is 1.05, based on the average in
the RCTs (see Table 1). Although the mean HAQ when patients start biologics in
the BSR register was 1.8,186 clinical opinion suggests that, in current
practice, clinicians are more likely to offer biologics early in the course of
the disease.<o:p></o:p></p>

<p class=MsoNormal>Clinical opinion suggests that about 50% of patients
starting biologics have mild or minimal psoriasis (&lt; 3% BSA or a PASI score
of &lt; 2.5), 25% have mild-to-moderate psoriasis (a baseline PASI score of
between 2.5 and 10), and 25% have moderate-to-severe psoriasis (a PASI score
&gt; 10) (Ian Bruce, Arc Epidemiology Unit, University of Manchester, UK, 20
November 2009, personal communication). Approximately 50% of patients in the
RCTs had &lt; 3% BSA psoriasis or a baseline PASI &lt; 2.5 (see Table 1),
indicating the trials are broadly representative of skin involvement in general
practice. We assume patients in the base case have mild-to-moderate psoriasis
with a PASI score of 7.5. The effect of biologic treatments in other patient
subgroups is explored in scenario analyses.<o:p></o:p></p>

<p class=MsoNormal>Model structure<o:p></o:p></p>

<p class=MsoNormal>The model is a cohort model, assuming a homogeneous baseline
population. The model has a Markov structure (see Figure 2). Patients enter the
model either (<span class=SpellE>i</span>) when commencing therapy with
etanercept, infliximab or adalimumab or (ii) with no therapy (assumed to be
palliative care only).<o:p></o:p></p>

<p class=MsoNormal><span style='mso-spacerun:yes'></span><o:p></o:p></p>

<p class=MsoNormal>FIGURE 2<o:p></o:p></p>

<p class=MsoNormal>Structure of the decision model, assuming patients continue
beyond 3 months if they achieve a <span class=SpellE>PsARC</span> response.<o:p></o:p></p>

<p class=MsoNormal>Initial response at 3 months<o:p></o:p></p>

<p class=MsoNormal>Table 33 shows the parameters used in the base-case model.
Initial response of the drug is defined in the model as <span class=SpellE>PsARC</span>
for joints and PASI 75 for psoriasis, based on the BSR149 and the BAD
guidelines173 (Box 2). These parameters were estimated by the evidence
synthesis (see Chapter 3, Efficacy of all three biologics).<o:p></o:p></p>

<p class=MsoNormal><span style='mso-spacerun:yes'></span><o:p></o:p></p>

<p class=MsoNormal>TABLE 33<o:p></o:p></p>

<p class=MsoNormal>Model parameters and assumptions used in the base case of
the York Assessment Group model.<o:p></o:p></p>

<p class=MsoNormal><span style='mso-spacerun:yes'></span><o:p></o:p></p>

<p class=MsoNormal>BOX 2<o:p></o:p></p>

<p class=MsoNormal>British Society for Rheumatology and BAD guidelines for
treatment response in patients with PsA and/or psoriasis. Primary joint
response: <span class=SpellE>PsARC</span> at 12 weeks/3 months Primary skin
response: PASI 75<o:p></o:p></p>

<p class=MsoNormal>The BAD guidelines highlight that the recommended time
points for assessing the initial response vary between drugs and between
guideline-making bodies. The licences for psoriasis recommend an assessment at
14 weeks for infliximab, at 12 weeks for etanercept and at 16 weeks for
adalimumab. Current NICE guidelines for psoriasis recommend an assessment at 10
weeks for infliximab. In the current appraisal we do not make these
distinctions and assume that an assessment is made for all drugs at around 3
months or between 12 and 16 weeks. The assessment of effectiveness in Chapter
3 (see Assessment of effectiveness) did not find any appreciable differences in
the biologics' response rates for joint disease or psoriasis between
approximately 12 weeks and 24 weeks.<o:p></o:p></p>

<p class=MsoNormal>In the decision model, the change in HAQ compared with
baseline is conditional on whether a <span class=SpellE>PsARC</span> response
was achieved. These parameters were estimated by the evidence synthesis in
Chapter 3, Efficacy of all three biologics. It is uncertain whether the change
in HAQ is the same for all <span class=SpellE>PsARC</span> treatment <span
class=GramE>responders, or</span> depends on the particular biologic treatment
followed. In the opinion of our clinical advisor, either scenario could be
plausible (Ian Bruce, personal communication). In the base-case model, we allow
the change in HAQ for treatment responders to depend on <span class=SpellE>PsARC</span>
response and the biologic <span class=GramE>treatment, and</span> consider the
alternative scenario as a sensitivity analysis. According to the evidence
synthesis in Appendix 5, the mean change in HAQ in the first 3 months for <span
class=SpellE>PsARC</span> responders, across all biologic drugs, is
&#8722;0.5688 [standard error (SE) 0.0315] and the mean change in HAQ for <span
class=SpellE>PsARC</span> non-responders, across all biologic drugs, is
&#8722;0.1697 (SE 0.0338).<o:p></o:p></p>

<p class=MsoNormal>During the initial 3-month trial period the model assumes
that patients on biologics have some improvement in HAQ even if they do not
reach the <span class=SpellE>PsARC</span> threshold. These parameters were
estimated by the evidence synthesis in Chapter 3, Efficacy of all three
biologics. Patients who do not achieve the required level of response during
the first 3 months and are withdrawn from therapy are assumed to return to the
same HAQ score after withdrawal as patients who had palliative care only.<o:p></o:p></p>

<p class=MsoNormal>The model assumes that patients who achieve a PASI 75
response will gain at least a 75% improvement in psoriasis compared with
baseline PASI. The calculation of the expected improvement in PASI for PASI 75
responders is described in Appendix 18. Patients who do not achieve a PASI 75
response will also have some proportionate gain in PASI while they continue
taking a biologic, although this will be less than a 75% improvement (see
Appendix 18).<o:p></o:p></p>

<p class=MsoNormal>A proportion of patients in the placebo arms of the RCTs
achieved a <span class=SpellE>PsARC</span> response and an improvement in HAQ.
Part of the response in both the placebo and treatment arms of RCTs may be due
to non-pharmacological aspects of medical care that would be common to both
arms (sometimes called a placebo or expectancy effect). It is uncertain
whether this effect would be reproducible in general practice.189 In the base
case we assume that part of the predicted response for treatment observed in
the trial is attributable to the controlled trial setting and would not be
reproducible in general practice. The change in HAQ in patients using biologics
is reduced by the mean change in HAQ across the placebo arms of the RCTs. A
similar adjustment is made for the expected change in PASI in patients using
biologic therapy. Appendix 9 gives further details of the conceptual framework
and adjustments made for the possible placebo/expectancy effects. An
alternative scenario assumes that the response rate to treatment in the RCTs is
fully generalisable to general practice and no adjustment for
placebo/expectancy effects is made.<o:p></o:p></p>

<p class=MsoNormal>Because there are two response variables (<span
class=SpellE>PsARC</span> and PASI), there are four possible outcomes at 3
months: skin response only, joints response only, response of both and response
of neither (Figure 2). The base-case model assumes that the responses to
psoriasis and arthritis might be correlated. Appendix 10 reviews the evidence
on the correlation between these responses and how the decision model
calculates the probabilities of each of the four outcomes at 3 months. An
alternative scenario assumes that the responses to psoriasis and arthritis are
independent.<o:p></o:p></p>

<p class=MsoNormal>The BSR guidelines recommend that biologics are withdrawn if
a <span class=SpellE>PsARC</span> response is not achieved at 3 months. This
rule is used in the base-case analysis of the model. However, in patients who
have significant skin and joint disease, some patients may achieve <span
class=SpellE>PsARC</span> but not PASI <span class=GramE>75, or</span> achieve
PASI 75 but not <span class=SpellE>PsARC</span>. In these cases, one could
specify that patients should continue biologic therapy irrespective of the
psoriasis response (BSR guideline), or those that respond to either can
continue (BAD guidelines) or (in principle at least) only those that achieve
both should continue. These alternative continuation rules are explored in
sensitivity analyses.<o:p></o:p></p>

<p class=MsoNormal>The model assumes that no patients withdraw due to adverse
events in the first 3 months. This is because the RCTs estimate responses on an
ITT basis, whereby withdrawals for any reason are considered treatment failures
and counted as non-response. Including withdrawals during the first 3 months in
the model would, therefore, be <span class=GramE>double-counting</span>.<o:p></o:p></p>

<p class=MsoNormal>Long-term outcomes and withdrawal from biologic therapy<o:p></o:p></p>

<p class=MsoNormal>If the decision is made to continue with the biologic
therapy beyond 3 months, it is assumed that patients maintain their initial
improvement in HAQ while on that therapy. This is based on evidence from an
opinion elicitation exercise from clinical <span class=GramE>experts, and</span>
supported by data on HAQ and <span class=SpellE>HRQoL</span> from biologics
registers.186,190 Appendix 11 describes the opinion elicitation methods and
results used to inform the model. It is assumed that patients maintain the
improvement in PASI while on biologic therapy. This assumption has been made in
other decision models (see Systematic review of existing cost-effectiveness
evidence).<o:p></o:p></p>

<p class=MsoNormal>There is an ongoing risk of withdrawal from biologic
therapy. Withdrawal might occur for lack of continuing efficacy (secondary
non-response), adverse events or other reasons. The rate of withdrawal after 3
months is assumed to be independent of the HAQ and PASI score in the model, to
be independent of whether the initial response was for both psoriasis and
arthritis or just arthritis, and to be constant over time. The rate is
estimated from a meta-analysis of registry data from several countries to be
&#8722;1.823 (SE 0.2044) on the log scale, or <span class=GramE>exp(</span>&#8722;1.823
+ 0.5  0.20442) = 0.165 per year (see Appendix 12). Although the registries
present withdrawal rates by drug, these data are not randomised and patient
cohorts starting on different biologic therapies are unlikely to be similar.191
Therefore, the decision model assumes the same withdrawal rates for all
biologics. Appendix 12 gives further details. As the withdrawal rate is
constant over time after the first 3 months, patients who achieve an initial <span
class=SpellE>PsARC</span> response will on average remain on biologic drugs for
just over 6 years in the model (1/0.165 = 6.06 years).<o:p></o:p></p>

<p class=MsoNormal>Patients withdraw from biologic to palliative care only. On
withdrawal, it is assumed that mean PASI returns to its initial score at
baseline (rebound equal to initial gain). There is considerable uncertainty
about change in HAQ associated with withdrawal (rebound). Previous modelling
work assumed rebound of HAQ follows either of two alternative scenarios, with
no data to inform which scenario is the more likely: rebound equal to initial <span
class=GramE>gain, and</span> rebound equal to natural history (NH).177 These
scenarios are explained in more detail in Appendix 11. The current model is
informed by the expert opinion elicitation exercise conducted with five
experts, described in Appendix 11. All experts suggested that not all the
initial gain in HAQ is lost following late withdrawal of patients who initially
responded to biologic therapy at 3 months. This scenario, that the HAQ rebound
might be less than initial gain, has not been considered in any of the previous
models of PsA, nor, to our knowledge, in any model of RA. Given the difficulty
and limitations of eliciting expert opinion and the novelty of these findings,
the current model assumes that rebound is equal to initial gain in the base <span
class=GramE>case, and</span> explores other scenarios (rebound less than
initial gain and rebound equal to NH) in sensitivity analyses.<o:p></o:p></p>

<p class=MsoNormal>Outcomes for patients on palliative care<o:p></o:p></p>

<p class=MsoNormal>The PASI is assumed not to change on average compared with
baseline for patients undergoing palliative care. HAQ is assumed to
progressively worsen in such patients at a constant rate, estimated by an
analysis requested from Deborah Symmons and colleagues at Manchester University
for this appraisal using data from the Norfolk Arthritis Register (NOAR) (see
details in Appendix 14).<o:p></o:p></p>

<p class=MsoNormal>Illustration of progression of HAQ in the model<o:p></o:p></p>

<p class=MsoNormal>Figure 3 illustrates the progression of HAQ over time for
three different patient histories in the model. For a patient whose arthritis
is controlled by biologic therapy, HAQ score is initially reduced (improves)
and then maintained over time. For a patient who does not start biologic
therapy, HAQ increases (deteriorates) over time to a maximum score of 3. For a
patient who withdraws at 5 years, HAQ rebounds (quickly increases) to the
baseline level after withdrawal and then increases at the same rate as those
who never started biologic therapy. However, in this scenario (rebound equal
to initial gain) the 5-year delay in progression obtained while on biologic
drugs is permanently maintained after withdrawal.<o:p></o:p></p>

<p class=MsoNormal><span style='mso-spacerun:yes'></span><o:p></o:p></p>

<p class=MsoNormal>FIGURE 3<o:p></o:p></p>

<p class=MsoNormal>Illustration of the progression of arthritis for a patient
successfully maintained on biologic, a patient without biologic and a patient
who withdraws at 5 years. Note: a greater HAQ score indicates worse disability.<o:p></o:p></p>

<p class=MsoNormal>Utility<o:p></o:p></p>

<p class=MsoNormal>Health utility is measured as a function of HAQ and PASI.
This relationship was estimated from analyses provided by the manufacturers,
who carried out linear regressions of EQ-5D utility versus HAQ and PASI in
participants in key RCTs (see Appendix 17). The base-case utility function is:<o:p></o:p></p>

<p class=MsoNormal>Expected utility = 0.897 &#8722; 0.298  HAQ &#8722; 0.004 
PASI<o:p></o:p></p>

<p class=MsoNormal>(Standard error)&#8195;(0.006) (0.006)&#8195;<span
class=GramE>&#8195;&#8195;&#8195;(</span>0.0003)<o:p></o:p></p>

<p class=MsoNormal>Other utility functions, supplied by the manufacturers, were
used as sensitivity analyses.<o:p></o:p></p>

<p class=MsoNormal>Figure 4 illustrates the change in utility over time for
different patients in the model. For a patient who is maintained on biologic
therapy, utility is initially improved <span class=GramE>as a consequence of</span>
the reduction in HAQ and PASI, the latter depending on the proportion of
patients who respond to psoriasis, given a response of arthritis (see Figure 2
and Appendix 10). This utility gain is assumed to be maintained over time. For
a patient who did not start biologic therapy, utility deteriorates over time to
a minimum value that is &lt; 0, indicating that the general population would
consider <span class=SpellE>HRQoL</span> with the severest arthritis symptoms
and uncontrolled psoriasis to be worse than death. For a patient who withdraws
at 5 years, utility rebounds to the baseline level after withdrawal and then
deteriorates at the same rate as those on NH. The area between these curves
(area A + C in Figure 4) represents the difference in lifetime QALYs between
a patient who withdraws at 5 years and a patient who never uses biologic
therapy.<o:p></o:p></p>

<p class=MsoNormal><span style='mso-spacerun:yes'></span><o:p></o:p></p>

<p class=MsoNormal>FIGURE 4<o:p></o:p></p>

<p class=MsoNormal>Illustration of utility (<span class=SpellE>HRQoL</span>) of
a patient successfully maintained on biologic, a patient without biologic and a
patient who withdraws at 5 years. Note: EQ-5D utility takes a maximum value of
1, indicating full health; values of &lt; 0 correspond (more...)<o:p></o:p></p>

<p class=MsoNormal>Time horizon for maintaining treatment effects<o:p></o:p></p>

<p class=MsoNormal>It is uncertain whether the effectiveness of biologic
therapy is maintained in the very long term. Previous models considered a
scenario where it is assumed that all patients withdraw from biologic therapy
at 10 years, and all gains in HAQ with respect to NH are lost at this point.177
Figure 4 illustrates the effect on utility of this 10-year time horizon for
treatment effects scenario compared with the base case that assumes that
treatment effects are maintained over the lifetime.<o:p></o:p></p>

<p class=MsoNormal>The difference in lifetime QALYs for a patient who is
maintained successfully on a biologic, compared with NH, is area A + B + C + D.
However, <span class=SpellE>if</span> is assumed that treatment effects last
for only 10 years, the difference in QALYs over 10 years between being on a
biologic and NH is only area A + B. For a patient who withdraws from a biologic
at 5 years, the difference in lifetime QALYs compared with NH is area A + C.
The difference in QALYs between assuming a 10-year time horizon and assuming a
40-year time horizon for a patient who withdraws from therapy at 5 years is
area C. Biologic therapy appears much more effective if it is assumed that
treatment effects in those who withdraw and those who do not withdraw are
maintained over the long term. The base-case model assumes that the benefits of
biologic therapy are maintained for a lifetime. Time horizons for treatment
remaining effective for up to 10 years and up to 20 years are considered in
sensitivity analyses.<o:p></o:p></p>

<p class=MsoNormal>Health service costs<o:p></o:p></p>

<p class=MsoNormal>The acquisition costs of the drugs and of their
administration and monitoring were obtained from BSR recommendations and
pharmaceutical list prices65 (see Appendix 13). The base case assumes that four
vials of infliximab are <span class=GramE>administered</span> and that vial
sharing is not permitted.<o:p></o:p></p>

<p class=MsoNormal>Health-care costs increase with severity of both arthritis36
and psoriasis.37 The health service costs of treating arthritis were measured
from a UK-based study that estimated the effect of HAQ on costs in patients
with RA41,59 (see Appendix 15). The NHS costs used for treating
mild-to-moderate psoriasis in patients who do not use biologics or who do not
respond to biologics were obtained from NHS unit costs of phototherapy187 and a
UK RCT.192 No UK studies based on prospective IPD were identified to estimate
the health service costs of treating moderate or severe psoriasis in patients
who do not use biologics or who do not respond to biologics. In the model these
costs were obtained from a Dutch RCT and adjusted to UK price levels188 (see
Appendix 16).<o:p></o:p></p>

<p class=MsoNormal>All-cause mortality<o:p></o:p></p>

<p class=MsoNormal>All-cause mortality was estimated from UK life tables. A
Gompertz function was fitted to these data (see Appendix 19). The base case
uses a published estimate of the additional mortality risk in PsA.29 The effect
of biologics on mortality in PsA is uncertain. The US VA study of MTX in
psoriasis and patients with RA found that MTX was associated with significantly
reduced incidence of vascular disease.193 Long-term control of chronic
inflammation may reduce mortality. However, long-term use of biologics might
increase other mortality risks. The decision model assumes that there is no
difference in mortality rates between treatments, or between biologic
treatments and no treatment.<o:p></o:p></p>

<p class=MsoNormal>Subgroup analyses<o:p></o:p></p>

<p class=MsoNormal>The base-case model assumes a cohort of patients with PsA
with baseline HAQ of 1.05, the mean of HAQ across the RCTs (see Table 1), and
mild-to-moderate psoriasis (baseline PASI of 7.5). The model considered other
cohorts in subgroup analyses:<o:p></o:p></p>

<p class=MsoNormal>&#61607;<span style='mso-tab-count:1'> </span>A
more severe baseline HAQ of 1.8, which is the mean HAQ of patients entering the
British Society for British Society for Rheumatology Biologics Register
(BSRBR).186<o:p></o:p></p>

<p class=MsoNormal>&#61607;<span style='mso-tab-count:1'> </span>No
skin involvement, with PASI of 0. Clinical opinion suggests 50% of patients
with PsA starting biologics in clinical practice would have mild or no skin
involvement (Ian Bruce, personal communication).<o:p></o:p></p>

<p class=MsoNormal>&#61607;<span style='mso-tab-count:1'> </span>A
baseline PASI of 12.5, corresponding to moderate-to-severe psoriasis.194,195
Clinical opinion suggests that 25% of patients with PsA starting biologics in
clinical practice would have a baseline PASI &gt; 10 (Ian Bruce, personal
communication).<o:p></o:p></p>

<p class=MsoNormal>The review described in Chapter 3 did not find any evidence
with which to assess whether treatment effects might differ by baseline
severity, and, consequently, these analyses assume no change in relative
treatment effects and focus just on variation between subgroups in baseline
severity.<o:p></o:p></p>

<p class=MsoNormal>The base-case model assumes patients have failed at least
two <span class=GramE>DMARDs, but</span> are naive to biologics at baseline.
The model was also used to estimate the cost-effectiveness of biologics used as
a second course of therapy, if the first biologic is withdrawn. For example, if
etanercept has been tried and failed, then the next alternative in sequence is
adalimumab, infliximab or no biologic therapy. The reason why the patient
failed the first course of therapy is potentially important information in
deciding on the second course. Therefore, we consider two subgroups: one who
failed the first biologic because of adverse events, and another who failed
because of lack of efficacy. No RCTs have evaluated outcomes in these
subgroups, and we estimate treatment response and withdrawal rates for these
subgroups from observational data from the BSR register, which showed that if a
patient failed first-line therapy for lack of efficacy, then the risk of
failing the second-line therapy for lack of efficacy increased by 2.7 (95% CI
2.1 to 3.4). If a patient failed first-line therapy because of an adverse <span
class=GramE>event</span> then the risk of failing the second-line therapy for
adverse events increased by 2.3 (95% CI 1.9 to 2.9).196 Appendix 20 describes
how these data were used to estimate the probability of initial response and
later withdrawal for biologic therapies used as second line.<o:p></o:p></p>

<p class=MsoNormal>Analytic methods<o:p></o:p></p>

<p class=MsoNormal>The uncertainty in each parameter was represented using a
probability distribution. The probabilities in Table 33 were assigned beta
distributions. If <span class=SpellE>p<span style='font-family:"Cambria Math",serif;
mso-bidi-font-family:"Cambria Math"'>&#8764;</span>Beta</span>(<span
class=GramE><span style='mso-ascii-font-family:Calibri;mso-hansi-font-family:
Calibri;mso-bidi-font-family:Calibri'>&#945;</span>,<span style='mso-ascii-font-family:
Calibri;mso-hansi-font-family:Calibri;mso-bidi-font-family:Calibri'>&#946;</span></span>)
then <span style='mso-ascii-font-family:Calibri;mso-hansi-font-family:Calibri;
mso-bidi-font-family:Calibri'>&#945;</span> = E(p) <span style='mso-ascii-font-family:
Calibri;mso-hansi-font-family:Calibri;mso-bidi-font-family:Calibri'></span>
E(p) <span style='mso-ascii-font-family:Calibri;mso-hansi-font-family:Calibri;
mso-bidi-font-family:Calibri'></span> (1 <span style='mso-ascii-font-family:
Calibri;mso-hansi-font-family:Calibri;mso-bidi-font-family:Calibri'>&#8722;</span>
E(p))/Var(p) and <span style='mso-ascii-font-family:Calibri;mso-hansi-font-family:
Calibri;mso-bidi-font-family:Calibri'>&#946;</span> = E(p) <span
style='mso-ascii-font-family:Calibri;mso-hansi-font-family:Calibri;mso-bidi-font-family:
Calibri'></span> (1 <span style='mso-ascii-font-family:Calibri;mso-hansi-font-family:
Calibri;mso-bidi-font-family:Calibri'>&#8722;</span> E(p)) <span
style='mso-ascii-font-family:Calibri;mso-hansi-font-family:Calibri;mso-bidi-font-family:
Calibri'></span> (1 <span style='mso-ascii-font-family:Calibri;mso-hansi-font-family:
Calibri;mso-bidi-font-family:Calibri'>&#8722;</span> E(p))/Var(p). The rate of
change of HAQ while not on treatment was assigned a gamma distribution to
ensure that values are strictly positive. If <span class=SpellE>x<span
style='font-family:"Cambria Math",serif;mso-bidi-font-family:"Cambria Math"'>&#8764;</span>Gamma</span>(<span
class=SpellE><span class=GramE>a,s</span></span>) then a = E(x) <span
style='mso-ascii-font-family:Calibri;mso-hansi-font-family:Calibri;mso-bidi-font-family:
Calibri'></span> E(x)/Var(x) and s = Var(x)/E(x). All other uncertain
parameters were assigned normal distributions with the mean and SE shown in
Table 33. Probabilistic sensitivity analysis was carried out using Monte Carlo
simulation.<o:p></o:p></p>

<p class=MsoNormal>The results of the model are presented in two ways. First,
mean lifetime costs and QALYs for the three strategies are reported and their
cost-effectiveness compared, estimating ICERs using standard decision rules.197
Briefly, the alternative strategies are ranked by mean cost. Strategies that
are more costly than another, but offer no greater expected benefit are known
as dominated<span class=GramE>, and</span> excluded. Strategies that are
dominated by a linear combination of other strategies are considered subject to
extended domination and are also excluded. ICERs are then calculated for each
of the remaining strategies, compared with the next best alternative. Although
NICE does not specify a particular cost-effectiveness threshold, a strategy is
more likely to be considered cost-effective if the ICER were &lt; 20,000 per
QALY, and less likely to be considered cost-effective if the ICER were &gt;
30,000 per QALY.184 Second, the decision uncertainty is shown as the
probability that each intervention is the most cost-effective for a given
cost-effectiveness threshold.<o:p></o:p></p>

<p class=MsoNormal>A series of alternative scenarios is also presented to
explore the effect of changing one or more parameters/assumptions in the model.<o:p></o:p></p>

<p class=MsoNormal>Results of York Economic Assessment<o:p></o:p></p>

<p class=MsoNormal>Estimated probabilities of response at 3 months in the base
case<o:p></o:p></p>

<p class=MsoNormal>Based on the results of the evidence synthesis in Chapter 3
(see Results of review of clinical effectiveness), and an estimate of the
correlation between <span class=SpellE>PsARC</span> and PASI 75 outcomes in
biologic therapy from an RCT,51 the model estimated the probability that a
patient would respond for psoriasis only, joints only, both outcomes or neither
outcome with each biologic therapy. These outcomes are shown under two assumptions:
positive correlation (base case) and independence (Table 34).<o:p></o:p></p>

<p class=MsoNormal><span style='mso-spacerun:yes'></span><o:p></o:p></p>

<p class=MsoNormal>TABLE 34<o:p></o:p></p>

<p class=MsoNormal>The mean probabilities of <span class=SpellE>PsARC</span>
and PASI 75 responses at 3 months.<o:p></o:p></p>

<p class=MsoNormal>Results of the base-case cost-effectiveness analysis<o:p></o:p></p>

<p class=MsoNormal>The results of the base-case cost-effectiveness analysis are
shown in Table 35, and univariate sensitivity analyses in Table 36. The
base-case analysis suggests that infliximab is the most effective treatment (in
terms of expected QALYs), followed by etanercept then adalimumab. Infliximab is
also the <span class=GramE>most costly</span> treatment, followed by etanercept
then adalimumab. The ICER of etanercept compared with palliative care is about
18,000, and the ICER of infliximab compared with etanercept is about 44,000
per QALY. Of the three biologic therapies, etanercept has the highest
probability of being cost-effective at a threshold of between 20,000 and
30,000 per QALY. Etanercept is the most cost-effective strategy in 44% of
simulations of the base-case model, at a threshold ICER of 20,000 and in 48%
of simulations at a threshold of 30,000 per QALY.<o:p></o:p></p>

<p class=MsoNormal><span style='mso-spacerun:yes'></span><o:p></o:p></p>

<p class=MsoNormal>TABLE 35<o:p></o:p></p>

<p class=MsoNormal>Results of the base-case analysis.<o:p></o:p></p>

<p class=MsoNormal><span style='mso-spacerun:yes'></span><o:p></o:p></p>

<p class=MsoNormal>TABLE 36<o:p></o:p></p>

<p class=MsoNormal>Univariate sensitivity analyses.<o:p></o:p></p>

<p class=MsoNormal>Adalimumab is extendedly dominated by palliative care and
etanercept. This means that if NICE were considering adalimumab, the ICER
relative to palliative care would be 26,470/1.409 = 18,786. However, the
expected QALY per patient achieved with etanercept is greater than for
adalimumab (7.00 vs 6.58), while the ICER of etanercept versus palliative care
is 17,853. Therefore, it would not, on average, be cost-effective to recommend
adalimumab because a greater QALY gain can be achieved from etanercept within
the threshold of 20,000 per QALY.<o:p></o:p></p>

<p class=MsoNormal>Expected QALYs are low in this model. The total lifetime
discounted health associated with palliative care is about 5.17 QALYs. This is
because the base-case scenario assumes that utility declines fairly rapidly in
patients with uncontrolled <span class=GramE>arthritis, and</span> may be &lt;
0 in later years (see Figure 4). For comparison, if HAQ and PASI could be
reduced to 0 for the complete time horizon of the model (40 years), the model
predicts that this cohort would expect 15 QALYs, given the rate of mortality,
the intercept of the utility function and the discount rate. Figure 5
partitions the lifetime discounted QALYs gained by biologic therapies into
those associated with improving arthritis and those associated with improving
psoriasis, relative to palliative care. In the base case, utility gains <span
class=GramE>as a result of</span> improvement in arthritis are predicted to be
much greater than utility gains as a result of improvement in the psoriasis
component of <span class=SpellE>PsA.</span><o:p></o:p></p>

<p class=MsoNormal><span style='mso-spacerun:yes'></span><o:p></o:p></p>

<p class=MsoNormal>FIGURE 5<o:p></o:p></p>

<p class=MsoNormal>Gains in lifetime discounted QALYs associated with treating
arthritis and psoriasis in PsA with biologic therapies relative to palliative
care.<o:p></o:p></p>

<p class=MsoNormal>The expected lifetime (40-year) discounted costs without
biologics (palliative care only) are about 42,000 in the base case for a
patient with PsA and mild-to-moderate psoriasis. This can be partitioned into
29,000 for the treatment of arthritis and 13,000 for the treatment of
psoriasis. Figure 6 partitions the total lifetime discounted health-care costs
of the strategies into costs associated with the acquisition, monitoring and
administration cost of the biologic drugs, the cost savings associated with
treating arthritis (i.e. the reduction in HAQ score) and the cost savings
associated with treating psoriasis (i.e. the reduction in PASI score). All
costs are shown relative to the costs of palliative care.<o:p></o:p></p>

<p class=MsoNormal><span style='mso-spacerun:yes'></span><o:p></o:p></p>

<p class=MsoNormal>FIGURE 6<o:p></o:p></p>

<p class=MsoNormal>Lifetime discounted costs of biologic drugs, and cost
savings for arthritis and psoriasis relative to non-biologic treatments for <span
class=SpellE>PsA.</span><o:p></o:p></p>

<p class=MsoNormal>The lifetime discounted acquisition, administration and
monitoring cost of infliximab is about 52,000; etanercept is about 33,000 and
adalimumab is about 27,000. These prescribing costs are much greater than any
offset health-care cost savings elsewhere. Infliximab is associated with the
greatest gains in PASI and HAQ, and the greatest cost savings. Adalimumab has
the second greatest gains in PASI and associated cost savings, and etanercept
has the second greatest gains in HAQ and associated cost savings.<o:p></o:p></p>

<p class=MsoNormal>Results of sensitivity analyses<o:p></o:p></p>

<p class=MsoNormal>Table 36 shows the results of the univariate sensitivity
analyses. Table 37 shows the cost-effectiveness of the alternatives in each of
the scenarios, <span class=GramE>assuming that</span> an ICER of 20,000 or
less is likely to be cost-effective and a strategy with an ICER of &#8805;
30,000 is unlikely to be accepted.<o:p></o:p></p>

<p class=MsoNormal><span style='mso-spacerun:yes'></span><o:p></o:p></p>

<p class=MsoNormal>TABLE 37<o:p></o:p></p>

<p class=MsoNormal>Cost-effectiveness of the strategies under different
scenarios.<o:p></o:p></p>

<p class=MsoNormal>The ICER of adalimumab falls below 20,000 per QALY and is
no longer dominated by other strategies in any of the following univariate
sensitivity analyses, assuming all other variables take mean values as in the
base case:<o:p></o:p></p>

<p class=MsoNormal>&#61607;<span style='mso-tab-count:1'> </span>All
responders to <span class=SpellE>PsARC</span> have the same change in HAQ at 3
months, regardless of biologic therapy used.<o:p></o:p></p>

<p class=MsoNormal>&#61607;<span style='mso-tab-count:1'> </span>If
etanercept and adalimumab are considered equally effective for <span
class=SpellE>PsARC</span> response, HAQ change and PASI response.<o:p></o:p></p>

<p class=MsoNormal>&#61607;<span style='mso-tab-count:1'> </span>A
patient who does not respond for psoriasis, or does not use biologic therapy,
undergoes annual inpatient psoriasis treatment rather than annual ultraviolet
light, type B (UVB), treatment.<o:p></o:p></p>

<p class=MsoNormal>The higher cost per PASI point (including phototherapy) from
the Schering-Plough model152 are used.<o:p></o:p></p>

<p class=MsoNormal>The ICER of etanercept increases above 20,000 per QALY or
is dominated by other strategies in any of the following univariate sensitivity
analyses, <span class=GramE>assuming that</span> all other variables take mean
values, as in the base case:<o:p></o:p></p>

<p class=MsoNormal>&#61607;<span style='mso-tab-count:1'> </span>A
patient who does not achieve a PASI 75 response is offered one course of
therapy as a hospital inpatient per year to treat psoriasis. The base case
assumed that these patients are offered UV therapy.<o:p></o:p></p>

<p class=MsoNormal>&#61607;<span style='mso-tab-count:1'> </span>HAQ
rebounds after withdrawal from biologic to NH rather than to initial gain.<o:p></o:p></p>

<p class=MsoNormal>&#61607;<span style='mso-tab-count:1'> </span>Biologic
treatment becomes ineffective (relative to no treatment) after 10 years.<o:p></o:p></p>

<p class=MsoNormal>&#61607;<span style='mso-tab-count:1'> </span>If
the Schering-Plough152 estimates of the cost of treating psoriasis with
phototherapy are used in the York Assessment Group model.<o:p></o:p></p>

<p class=MsoNormal>The ICER of infliximab falls below 30,000 per QALY in any
of the following univariate sensitivity analyses, <span class=GramE>assuming
that</span> all other variables take mean values as in the base case:<o:p></o:p></p>

<p class=MsoNormal>&#61607;<span style='mso-tab-count:1'> </span>A
patient who does not respond for psoriasis, or does not use biologic therapy,
undergoes annual inpatient psoriasis treatment rather than annual UVB
treatment.<o:p></o:p></p>

<p class=MsoNormal>&#61607;<span style='mso-tab-count:1'> </span>Infliximab
requires three vials rather than four vials per administration.<o:p></o:p></p>

<p class=MsoNormal>&#61607;<span style='mso-tab-count:1'> </span>The
higher cost per PASI point (including phototherapy) from the Schering-Plough152
model are used.<o:p></o:p></p>

<p class=MsoNormal>&#61607;<span style='mso-tab-count:1'> </span>HAQ
improves while on a biologic drug.<o:p></o:p></p>

<p class=MsoNormal>No biologic appears cost-effective at a threshold of 30,000
per QALY if rebound of HAQ is to NH, rather than initial gain. In the scenario
where treatment remains effective for only up to 10 years, the ICER for
etanercept versus palliative care is 31,000 per QALY and <span class=GramE>is
therefore is</span> likely to be on the boundary of what would be considered
cost-effective. If treatment remains effective for up to 20 <span class=GramE>years</span>
then the ICER of etanercept versus palliative care is 19,000 per QALY and the
ICER for infliximab versus etanercept is 60,000 per QALY.<o:p></o:p></p>

<p class=MsoNormal>It should be noted that these are univariate analyses, where
one variable in the base case is changed, holding others constant. Changes in
combinations of variables might generate different results.<o:p></o:p></p>

<p class=MsoNormal>Results of subgroup analyses<o:p></o:p></p>

<p class=MsoNormal>Table 38 shows the results of the subgroup analyses.<o:p></o:p></p>

<p class=MsoNormal><span style='mso-spacerun:yes'></span><o:p></o:p></p>

<p class=MsoNormal>TABLE 38<o:p></o:p></p>

<p class=MsoNormal>Subgroup analyses.<o:p></o:p></p>

<p class=MsoNormal>Biologics are slightly less cost-effective if the baseline
HAQ is 1.8; however, etanercept still has an ICER below 20,000 per QALY. In
this model, the size of the absolute gain in HAQ for responders is assumed to
be independent of baseline HAQ, although there is a ceiling effect as the
maximum HAQ score is 3. There is less scope for biologics to alter the course
of the disease if they are started when patients already have a high degree of
disability.<o:p></o:p></p>

<p class=MsoNormal>Etanercept is the most cost-effective strategy in patients
with negligible baseline psoriasis. The ICER of infliximab versus etanercept
increases to 65,000 per QALY. If baseline PASI were moderate-to-severe (12.5
instead of 7.5) the ICER of adalimumab versus palliative care would be &lt;
16,000 per QALY, the ICER of etanercept versus adalimumab would be around
19,000 per QALY and the ICER of infliximab versus etanercept would be about
28,000 per QALY. If patients with uncontrolled moderate-to-severe psoriasis
receive annual inpatient treatment instead of annual UVB the ICER for
infliximab is below 20,000 per QALY and it is likely to be the most
cost-effective strategy.<o:p></o:p></p>

<p class=MsoNormal>If the patient is indicated for biologics because of both
severe skin disease and severe joint disease, we can consider alternative rules
for continuing therapy. The base case follows the BSR guidelines, i.e.
treatment is withdrawn from patients who fail to achieve the <span
class=SpellE>PsARC</span> response within 3 months of treatment. Alternative
decision rules (see Box 2) can change the conclusions. If patients with PsA and
moderate-to-severe psoriasis are allowed to continue beyond 3 months if they
respond to either <span class=SpellE>PsARC</span> or PASI 75 then all biologics
have a similar probability of being cost-effective at a threshold of 20,000
per QALY, and infliximab has the highest probability of being cost-effective at
a threshold of 30,000 per QALY. If patients with PsA and moderate-to-severe
psoriasis are allowed to continue beyond 3 months only if they respond to both <span
class=SpellE>PsARC</span> and PASI 75 then infliximab has the highest
probability of being cost-effective at thresholds of 20,000 and 30,000 per
QALY.<o:p></o:p></p>

<p class=MsoNormal>Table 39 shows the outcomes for each strategy if the
biologic drugs are used as a second course of therapy after a first biologic
has failed for patients with PsA with mild-to-moderate skin disease. The ICERs
depend on which drug was used as first-line therapy, and which is therefore
ineligible for use as <span class=GramE>second-line</span>.<o:p></o:p></p>

<p class=MsoNormal><span style='mso-spacerun:yes'></span><o:p></o:p></p>

<p class=MsoNormal>TABLE 39<o:p></o:p></p>

<p class=MsoNormal>Costs and QALYs of biologics used as second-line therapy for
patients with mild-to-moderate skin disease if first biologic fails.<o:p></o:p></p>

<p class=MsoNormal>&#61607;<span style='mso-tab-count:1'> </span>For
patients who failed adalimumab as first line for inefficacy, etanercept has an
ICER of &lt; 20,000, and the ICER for infliximab is above 40,000 per QALY.<o:p></o:p></p>

<p class=MsoNormal>&#61607;<span style='mso-tab-count:1'> </span>For
patients who failed etanercept as first line for inefficacy, adalimumab has an
ICER of &lt; 20,000 and infliximab is around 25,000 per QALY.<o:p></o:p></p>

<p class=MsoNormal>&#61607;<span style='mso-tab-count:1'> </span>For
patients who failed infliximab as first line for inefficacy, etanercept has an
ICER of &lt; 20,000 per QALY and adalimumab is extendedly dominated compared
with palliative care and etanercept.<o:p></o:p></p>

<p class=MsoNormal>&#61607;<span style='mso-tab-count:1'> </span>The
ICERs are broadly similar for patients who failed first-line therapy for
adverse effects compared with results for those who failed first-line therapy
for inefficacy.<o:p></o:p></p>

<p class=MsoNormal>Go to:<o:p></o:p></p>

<p class=MsoNormal>Comparison of the York Economic Assessment with the
manufacturers' models<o:p></o:p></p>

<p class=MsoNormal>The following sections compare the assumptions and data
sources used in each of the industry models with the current York model (see
York Economic Assessment). A full description of the three industry models is
provided in Appendix 7 and a critique is detailed in Appendix 8.<o:p></o:p></p>

<p class=MsoNormal>Summary of the models' results<o:p></o:p></p>

<p class=MsoNormal>The three industry models, along with the current York
model, are all potentially relevant to address the decision problem as
specified by the NICE scope. However, each generates a different set of
results. Abbott's base case151 is for a 40-year time horizon, baseline HAQ =
1.3, baseline PASI = 6.9, proportion with psoriasis = 40%, and rebound of HAQ
after withdrawal from biologic therapy equal to initial gain. Only results
averaged across all patients are presented in the base case. The results show
that infliximab was associated with the highest QALYs (8.49), followed by
etanercept and adalimumab (both 8.33) and then DMARDs (7.47). Infliximab is the
<span class=GramE>most costly</span> strategy (104,772). The ICER for
adalimumab compared with DMARDs is 29,827. Etanercept is dominated by
adalimumab and infliximab has an ICER of 199,596 compared with adalimumab.<o:p></o:p></p>

<p class=MsoNormal>Schering-Plough's base case152 is for a 40-year time
horizon, baseline HAQ = 1.14, baseline PASI = 11, proportion with psoriasis =
66% and rebound equal to gain. Results are reported for all patients, psoriatic
patients and non-psoriatic patients. The results show that palliative care is
the strategy associated with the lowest QALYs in all base-case scenarios
(5.796.68, depending on the group of patients). Infliximab is the most
effective strategy for all patients with PsA and those with a psoriasis component
(8.65 QALYs for all patients and 8.40 QALYs for patients with psoriasis). For
patients without psoriasis, etanercept is the most effective (9.14 QALYs). For
all patients the model estimates a total cost of 64,704 for palliative care,
99,278 for adalimumab, 108,481 for etanercept and between 107,954 and
123,475 for infliximab, depending on the weight of patients. Similar estimates
were generated for minimal psoriasis and psoriasis patients separately.
Therefore, for all patients, etanercept has an ICER of 12,606 (compared with
adalimumab) assuming a patient weight of 70 or 80 kg. For a 60-kg patient
etanercept has an ICER of 12,432, compared with adalimumab, for patients
without psoriasis. Infliximab dominates etanercept for psoriatic patients and
all patients.<o:p></o:p></p>

<p class=MsoNormal>Wyeth's base case153 is for a 40-year time horizon, baseline
HAQ = 0.69, baseline PASI = 3.39, proportion with psoriasis = 62.4% and rebound
equal to gain. Only results for all patients are presented in the base case.
The results show that etanercept was associated with the highest gain in QALYs
(6.90) followed by adalimumab (6.54), infliximab (6.39) and then ciclosporin
(5.96). Ciclosporin was associated with the lowest cost (53,860). Infliximab
had the highest total costs (66,867). Etanercept is the most cost-effective
strategy with an ICER of 12,480.<o:p></o:p></p>

<p class=MsoNormal>The base-case analysis in the York model assumes a lifetime
time (40-year) horizon for costs and QALYs a baseline HAQ = 1.05, baseline PASI
= 7.5, rebound equal to gain and incorporates the correlation between <span
class=SpellE>PsARC</span> and PASI 75 outcomes. The results for the base case
for patients with PsA and mild-to-moderate psoriasis show that infliximab is
the most effective treatment followed by etanercept then adalimumab. Infliximab
is also the <span class=GramE>most costly</span> treatment, followed by
etanercept then adalimumab. The ICER of etanercept compared with palliative
care is 18,000. Adalimumab is extendedly dominated. The ICER for infliximab
compared with etanercept is 44,000 per QALY. Results are also presented for
other baseline subgroups: HAQ = 1.8, PASI = 0 and PASI = 12.5.<o:p></o:p></p>

<p class=MsoNormal>Critique of manufacturers' submissions and justification for
current York modelling approach<o:p></o:p></p>

<p class=MsoNormal>There are large differences in the results generated by each
of the four models. <span class=GramE>In order to</span> determine which model
provides the most appropriate estimates of the cost-effectiveness of biologics
for the treatment of PsA, the key features of the models are compared and
contrasted in more detail in the sections below. Justification for the approach
taken in the current York model is also presented. A full critique of the
industry models is also presented in Appendix 8. Table 40 shows the key
features of each of the models. A full description of the three industry models
is provided in Appendix 7.<o:p></o:p></p>

<p class=MsoNormal><span style='mso-spacerun:yes'></span><o:p></o:p></p>

<p class=MsoNormal>TABLE 40<o:p></o:p></p>

<p class=MsoNormal>Comparison of the key features of each of the models.<o:p></o:p></p>

<p class=MsoNormal>Choice of comparator<o:p></o:p></p>

<p class=MsoNormal>The choice of comparator is crucial in determining the
relative cost-effectiveness of biologics. In comparing biologics to DMARDs
while using the effectiveness estimates of placebo from randomised trials (i.e.
assume DMARD cost and placebo effectiveness), Wyeth153 and Abbott151 may
artificially inflate the cost-effectiveness of biologics, as DMARDs are liable
to be more effective than palliative care in practice. It is also unlikely that
patients who have failed two previous DMARDs would be considered for further
DMARD treatment, and such patients are likely to receive palliative care (as
assumed in the York and Schering-Plough152 models).<o:p></o:p></p>

<p class=MsoNormal>Heterogeneity<o:p></o:p></p>

<p class=MsoNormal>Although patients included in the model will be similar in
terms of their exposure to DMARDs and the fact that they will be biologic
naive, they may be a heterogeneous group in many other respects. The Abbott151
and Wyeth153 models use an individual sampling approach, where observed
heterogeneity in the group of patients is modelled by sampling over a set of
patient characteristics, taken from Mease et al.200 This approach effectively
averages over the heterogeneity between patients. In contrast, the Schering-Plough152
and current York models use a cohort approach which assumes a homogeneous group
of patients. To account for any heterogeneity in a cohort model, the models can
be <span class=GramE>ran</span> separately for each homogeneous group to
generate estimates of cost-effectiveness, conditional on each set of observed
characteristics. In principle, separate NICE decisions can then made for each
group of patients. This difference in how heterogeneity is reflected in the
different models may partly explain the variation in their results.<o:p></o:p></p>

<p class=MsoNormal>Baseline characteristics differ quite markedly between
models. In the Wyeth model153 the baseline HAQ and PASI are both low, at 0.69
and 3.39, respectively. These are higher in the Abbott151 model at 1.3 for HAQ
and 6.9 for PASI. In the Schering-Plough152 model baseline HAQ is about the
average for the RCTs at 1.14; however, a baseline PASI score of 11 suggests
that patients have relatively severe psoriasis. The Schering-Plough152 model
also includes the highest proportion of patients with psoriasis at 66%;
however, these are run as a separate subgroup to those without any significant
psoriasis rather than as a model input. The current York model also
distinguishes between those with little or no psoriasis (PASI scores &lt; 5)
and moderate or severe psoriasis (PASI scores &gt; 5) with 7.5 as the base
case. Baseline HAQ in the York model is 1.05, based on the average observed in
the RCTs (see Table 1). The current York model also run a series of scenarios
to vary base-case HAQ and PASI scores (see Tables 36 and 38). For patients with
a high baseline PASI (12.5) adalimumab is no longer extendedly dominated (ICER
is 16,000 compared with palliative care). The ICER for etanercept is <span
class=GramE>similar to</span> the base case at 19,000 compared to adalimumab
and the ICER for infliximab falls to 28,000 compared to etanercept. These
changes in ICERs are because of the differences in PASI response rates between
the drugs. For more severe psoriasis (high baseline PASI), treatments with a
better effect on PASI will be more cost-effective. For patients without any
significant psoriasis aspect to their disease, the ICER for etanercept
increases slightly to 19,000 compared with palliative care. For patients with
a higher baseline HAQ (1.8) the ICER for etanercept also increases to 19,000
compared with palliative care.<o:p></o:p></p>

<p class=MsoNormal>Model structure<o:p></o:p></p>

<p class=MsoNormal>The basic structure in each of the four models is similar.
Each determines initial response to treatment and then tracks HAQ and PASI
scores over a lifetime, taking account of any withdrawals from treatment.<o:p></o:p></p>

<p class=MsoNormal>Measurement of initial response for joints<o:p></o:p></p>

<p class=MsoNormal>All models use <span class=SpellE>PsARC</span> to measure
the initial response for joints. All models used a Bayesian evidence synthesis
to estimate <span class=SpellE>PsARC</span>. However, the results differ,
partly because different RCTs are included in the analyses (see Table 19).
Schering-Plough152 and the York model predict that infliximab is the most
effective drug for <span class=SpellE>PsARC</span> response, then etanercept,
then adalimumab. Wyeth153 predict etanercept is the most effective, then
infliximab, then adalimumab (see Table 21). Using a bivariate meta-analysis to inform
the economic model, Abbott151 predicts that infliximab is most effective for <span
class=SpellE>PsARC</span> and ACR responses, then adalimumab, then etanercept.
These differences have a substantial effect on the results of the economic
analysis. The sensitivity analysis shown in Table 36 shows that by assuming
that all treatments have the same probability of psoriasis responses (PASI
50/75/90) at 3 months, the ICER for etanercept falls to 16,000, adalimumab
remains extendedly dominated and the ICER for infliximab increases to over
66,000. This is because infliximab had a much higher probability of skin
response in the base case. Applying the same <span class=SpellE>PsARC</span>
response at 3 months to all treatments also has a minimal effect on the ICERs
of adalimumab and <span class=GramE>etanercept, but</span> increases the ICER
for infliximab compared with etanercept to over 100,000. This is because
infliximab was associated with a much higher <span class=SpellE>PsARC</span>
response in the base case (see Table 34).<o:p></o:p></p>

<p class=MsoNormal>Continuation on biologic treatment after initial assessment<o:p></o:p></p>

<p class=MsoNormal><span class=GramE>All of</span> the industry models assume
that patients are withdrawn from treatment if they are <span class=SpellE>PsARC</span>
non-responders at 12 weeks (and 24 weeks for Wyeth153), irrespective of PASI
response. The current York model also uses this assumption in the base case,
but additionally explores alternative scenarios for discontinuation for
patients who are indicated for both moderate-to-severe psoriasis and arthritis.
The BAD guidelines recommend that patients continue if they achieve <span
class=SpellE>PsARC</span> or PASI 75, although this continuation rule does not
change the conclusions for patients with PsA and mild-to-moderate psoriasis.<o:p></o:p></p>

<p class=MsoNormal>Correlation between skin and join response<o:p></o:p></p>

<p class=MsoNormal>If patients have both joints and skin involvement at
baseline then in determining the initial response to treatment it is important
to incorporate any correlation between the joint and skin responses, measured
by <span class=SpellE>PsARC</span> and PASI respectively. The current York
model incorporates the correlation between <span class=SpellE>PsARC</span> and
PASI 75 using data from the ADEPT trial88 and the results of the evidence
synthesis in Chapter 3 (see Results of review of clinical effectiveness) to
estimate the probability of a response to both psoriasis and joints, the
probability of a response to neither, <span class=GramE>and</span> the
probability of a response to one but not the other. The industry models, in
contrast, do not afford this issue as much attention. Abbott151 assumes that <span
class=SpellE>PsARC</span> and PASI responses are independent (see Appendix 7
for further detail). The Schering-Plough model152 predicts PASI by <span
class=SpellE>PsARC</span> response, thus generating a different PASI change for
<span class=SpellE>PsARC</span> responders and non-responders by drug. This
implicitly incorporates a correlation between <span class=SpellE>PsARC</span>
and PASI <span class=GramE>responses, but</span> is difficult to vary in
sensitivity analysis. The Wyeth model153 assumes PASI is a linear predictor of
HAQ (see Appendix 7 for further detail). This is a strong assumption that is
difficult to vary in sensitivity analysis, and Wyeth153 did not support this by
a clinical justification. The York model also considers a scenario where there
is no correlation between PASI 75 and <span class=SpellE>PsARC</span> (see
Table 36). The impact on the ICER for etanercept is minimal, however, with the
ICER for etanercept increasing to 16,106.<o:p></o:p></p>

<p class=MsoNormal>Effect on joints and skin for responders and non-responders<o:p></o:p></p>

<p class=MsoNormal>The models differ in the variables used to predict the
change in HAQ for responders. Wyeth153 estimate HAQ from <span class=SpellE>PsARC</span>
response and PASI. Abbott151 estimate HAQ from ACR response (assumed correlated
with <span class=SpellE>PsARC</span>) and other clinical and demographic
variables. Abbott151 assumes the ACR response varies by biologic drug, after
conditioning on <span class=SpellE>PsARC</span>. Schering-Plough152 and the
York model estimate HAQ from <span class=SpellE>PsARC</span> response, and
assume that HAQ varies by biologic received, after conditioning on <span
class=SpellE>PsARC</span> response.<o:p></o:p></p>

<p class=MsoNormal>Given the initial response (or lack of response) to
treatment, all models then determine an associated HAQ and PASI score. The
current York model uses the same approach as Schering-Plough,152 and predicts
HAQ by <span class=SpellE>PsARC</span> response and treatment, and this is
estimated by the evidence synthesis model. Abbott151 predicts HAQ from the ACR
response as an explanatory variable, and other clinical and demographic
explanatory variables. The same HAQ gain is assumed for all treatments, after
conditioning on ACR. Despite this, the Abbott model151 allows a different HAQ
gain for <span class=SpellE>PsARC</span> responders for each treatment. This is
because ACR response is assumed to differ by biologic drug, and ACR was
correlated with <span class=SpellE>PsARC</span> in the Abbott151 evidence
synthesis (see Table 19). Although this seems an attractive method of
predicting changes in HAQ, it was decided not to use this approach in the York
model as the Abbott151 evidence synthesis was very complex. Furthermore, it is
not clear what data used in the Abbott151 evidence synthesis inform their
economic model. In the clinical section of the Abbott report,151 Table 2.7.2.2
shows the marginal probabilities of <span class=SpellE>PsARC</span> and ACR
responses were estimated to be higher for etanercept than adalimumab (these
results are reproduced in Tables 5.21 and 5.24 of the York Assessment Group
report and are <span class=GramE>similar to</span> those of the York Assessment
Group). However, Table 3.4.3.1.1 of the economic section of the Abbott
report151 shows the contingent or joint probabilities of ACR and <span
class=SpellE><span class=GramE>PsARC</span></span><span class=GramE>, and</span>
appears to contradict the results of their clinical section; in this table,
adalimumab is shown as more effective for <span class=SpellE>PsARC</span> and
ACR response than etanercept. It appears that the Abbott meta-analysis151 that
informed their economic section made use of different data to the clinical
section, including data from biologics that are not relevant to this appraisal.<o:p></o:p></p>

<p class=MsoNormal>Wyeth153 estimates the initial change in HAQ, including
changes in PASI in the regression. The same HAQ gain is used for all
treatments. The use of the skin component of PsA to predict the arthritis
component of the disease is considered of doubtful clinical validity. There is
no evidence to suggest that one component of the disease is a good predicator
of the other: patients can have differing degrees of both components and those
with severe arthritis will not <span class=GramE>necessary</span> have severe
psoriasis and vice versa.<o:p></o:p></p>

<p class=MsoNormal>The fact that two of the models use treatment specific HAQ
gains (Schering-Plough152 and York) and two use the same HAQ gain for all
treatments may explain some of the variability in results. The results of a
sensitivity analysis on the York model (see Table 36) show that by assuming all
biologics have the same change in HAQ at 3 months for a <span class=SpellE>PsARC</span>
responder, the results differ quite significantly from those in the base case.
Adalimumab is no longer extendedly dominated and the ICER for etanercept
increases to 22,000 compared with adalimumab. This is because in the base case
etanercept was associated with a much higher HAQ gain for a <span class=SpellE>PsARC</span>
responder (0.63) than adalimumab (0.48).<o:p></o:p></p>

<p class=MsoNormal>To determine the initial change in PASI, the current York
model and the Abbott151 model predict the initial 12-week (and 24-week for
Abbott151) change in PASI, using baseline PASI and the proportion of patients
who are PASI 50/75/90 responders, thereby using all information on PASI
response. Wyeth153 uses only PASI-75 to generate the initial improvement in
PASI, thereby ignoring <span class=GramE>all of</span> the other PASI
information. Schering-Plough152 also estimates PASI change (not specifying
which proportion) in the initial <span class=GramE>period, but</span> do this
for <span class=SpellE>PsARC</span> responders/non-responders in their evidence
synthesis model. It is not clear why PASI change was estimated for <span
class=SpellE>PsARC</span> responders and non-responders and not for PASI
responders. Determining the initial differences in PASI response between
treatments is likely to be a key driver of the cost-effectiveness results. <span
class=GramE>All of</span> the evidence syntheses predicted that infliximab is
most effective for psoriasis response, then adalimumab, then etanercept (see
Table 23). However, Wyeth153 predicted that infliximab was less effective in
absolute terms than the York and Abbott151 models. The sensitivity analysis
shown in Table 36 shows that by assuming that all treatments have the same
probability of psoriasis responses (PASI 50/75/90) at 3 months, etanercept
appears more cost-effective and the other biologic drugs less cost-effective
than the base case.<o:p></o:p></p>

<p class=MsoNormal>Placebo effects<o:p></o:p></p>

<p class=MsoNormal>In determining this initial impact of treatment, it is
important to account for any overestimate of the absolute response rates in
both placebo and treatment groups in RCTs, compared with what would be expected
in routine practice. This is termed the placebo adjustment. However, the York
sensitivity analysis found that this adjustment had a minor effect on results.<o:p></o:p></p>

<p class=MsoNormal>Health Assessment Questionnaire progression when not on a
biologic<o:p></o:p></p>

<p class=MsoNormal>For those patients who do not respond to treatment, or who
are assigned palliative care, HAQ and PASI progression must be tracked over the
model. To determine HAQ progression off treatment, <span class=GramE>all of</span>
the industry models use data from the Leeds cohort study201 data. As detailed
in Appendix 14, however, the Leeds data set does have some limitations. The
current York model therefore uses data from patients enrolled in the NOAR (see
Appendix 14) data set to estimate HAQ change in patients who have uncontrolled <span
class=SpellE>PsA.</span> The 3-month progression rates are <span class=GramE>similar
to</span> those generated using the Leeds data (0.018 in NOAR compared with
0.016 in Leeds data set) and is unlikely to lead to major differences in the
results.<o:p></o:p></p>

<p class=MsoNormal>Withdrawal from biologics<o:p></o:p></p>

<p class=MsoNormal>For those patients who do initially respond to biologic
treatment, each of the models considers the possibility that they may withdraw
from treatment beyond the initial period due to either loss of efficacy or
adverse events. Each of the industry models makes use of a single data set to
estimate withdrawals. Schering-Plough152 uses the same rates as used in the
previous York model (0.11 per year from <span class=SpellE>Geborek</span> et
al.198). Wyeth153 and Abbott151 use evidence from a recent paper by Saad et
al.,191 which used data from the BSRBR registry to estimate parameters of a
Weibull distribution to quantify the rate of withdrawal over time. All models
assumed that withdrawal rates did not vary by treatment. However, the
sensitivity analysis reported in Table 36 shows that there is very little
impact of changes withdrawal rates within the current York model.<o:p></o:p></p>

<p class=MsoNormal>Sequential biologic therapies<o:p></o:p></p>

<p class=MsoNormal>Once patients withdraw from biologic <span class=GramE>treatment</span>
they are assumed to move to either palliative care or DMARDs. None of the four
models consider the use of sequential biologics in the base-case scenario. The
sequential use of biologics is common in clinical practice; however, a lack of
data on the effectiveness of biologics beyond first line use limits the scope
to consider such an analysis. The current York model conducts an exploratory
sensitivity analysis on the issue of sequencing biologics (see Appendix 20),
utilising available registry data on response rates for subsequent lines of
biologics.<o:p></o:p></p>

<p class=MsoNormal>Utility and cost estimates<o:p></o:p></p>

<p class=MsoNormal>The utilities and costs assigned to treatments are of
paramount importance in determining the cost-effectiveness of the included
treatments. It is, therefore, important to note that each of the models uses
different methodology and data sources to link HAQ and PASI to utilities and to
determine the associated costs of treatments. In generating utilities each of
the industry models uses both different data sources and different models to
predict utilities from HAQ and PASI. To disentangle these two effects the
current York model explores various scenarios using regression results provided
on request from each of the manufacturers (see Appendix 17), which are
estimated using a common methodology. In addition, the York model explores the
use of alternative assumptions regarding the calculation of utilities in
sensitivity analysis (see Table 36). Only the scenario where a higher estimate
of the effect of a unit change in HAQ on utility is taken from the Wyeth153
submission (0.45) has a discernible impact on the results. Etanercept is more
cost-effective (ICER is 12,000 compared with palliative care) and the ICER for
infliximab falls to 37,000.<o:p></o:p></p>

<p class=MsoNormal>Resource use assumed in establishing drug, administration
and monitoring costs differs between the industry models. <span class=GramE>In
particular, there</span> were varying assumptions regarding the number of doses
given for each of the drugs (see Appendix 8) and the number of laboratory tests
required for monitoring patients. The costs attached to hospital visits also
differed between models. In the Abbott model,151 it was not possible to
validate the resource use and costs used, and the total costs given in the
report could not be replicated in terms of the resource use items and unit
costs presented. That is, using the resource use multiplied by the respective
unit costs gave different total costs to those presented in the model report.
These also differed from those used in the model.<o:p></o:p></p>

<p class=MsoNormal>The current York model therefore sought to generate costs
for each of the treatments using resource use specified by the BSR guidelines
and validated by clinical collaborators (see Appendix 13). These differences in
costing methodology produce quite different estimates of total costs. For
example, in the initial 3-month period the cost of infliximab in the base-case
analysis is 5459 in the Abbott model,151 4386, in the Schering-Plough
model,152 6286 in the Wyeth model153 and 5522 in the current York model. The
sensitivity analysis in Table 36 shows the impact of varying drug costs in the
current York model. Using the costs presented in the Wyeth submission153 in the
York model (which are higher for infliximab (see Appendix 8) but lower for
adalimumab and etanercept than the York estimates, increases the
cost-effectiveness of etanercept and increases the ICER for infliximab
(69,000). Reducing the number of vials used for each infliximab infusion from
four to three greatly increases the cost-effectiveness of infliximab and
reduces the relative cost-effectiveness of the other biologics.<o:p></o:p></p>

<p class=MsoNormal>In addition to the costs of drugs, administration and
monitoring each of the models considers the ongoing health-service costs of PsA
as a function of a patient's HAQ score. Abbott151 and Schering-Plough152 also
include health-service costs according to PASI scores. The costs associated
with PASI score, <span class=GramE>in particular differ</span> quite markedly
(see Appendix 8). Abbott151 and Schering-Plough152 rely on surveys of
clinicians' opinions, based on vignettes of typical cases to estimate the
costs associated with treating psoriasis. The York model estimates the costs of
treating mild-to-moderate psoriasis that is uncontrolled by biologic drugs from
a UK RCT and the costs of treating moderate-to-severe psoriasis that is
uncontrolled by biologic drugs from a Dutch RCT. The sensitivity analysis in
Table 36 shows the impact of varying ongoing costs of PsA as a function of a
patient's HAQ and PASI score in the current York model. Using the exponential
HAQ cost function from the Abbott model151 reduces the ICER for etanercept to
13,000. Adding in a high inpatient cost of uncontrolled psoriasis had a much
more dramatic impact on model results: etanercept is dominated by infliximab,
which is itself associated with an ICER of 13,000 compared with adalimumab.
This reflects the beneficial effect of infliximab in terms of reducing PASI
score compared with other biologics. Infliximab is associated with an ICER
likely to be below the threshold when the cost estimates per PASI point
(including phototherapy) from Schering-Plough152 are used. In this situation
the ICER for infliximab is 20,000. Other sensitivity analysis on costs
dependent on HAQ and PASI had little impact on the model results.<o:p></o:p></p>

<p class=MsoNormal>Summary<o:p></o:p></p>

<p class=MsoNormal>The key differences between the three industry models and
the current York model have been discussed. This has highlighted a number of
potentially important limitations with the three industry models, in
particular: the choice of comparator, averaging across patient heterogeneity;
failure to consider alternative correlations between response types; how
initial <span class=SpellE>PsARC</span> response is determined; how the change
in HAQ is determined; no consideration of alternative decision rules about
continuing beyond the initial 3-month period; generating withdrawals rates from
a single observational study; the costs of drugs; drug administration and
monitoring; and the health-care costs associated with treating arthritis and
psoriasis if these are uncontrolled by biologics.<o:p></o:p></p>

<p class=MsoNormal>Go to:<o:p></o:p></p>

<p class=MsoNormal>Discussion of York Economic Assessment<o:p></o:p></p>

<p class=MsoNormal>The economic model has evaluated the cost-effectiveness of
three alternative biologic therapies and palliative care only. Under base-case
assumptions, for patients with PsA and mild-to-moderate skin disease, the ICER
of etanercept versus palliative care is about 18,000 per QALY and the ICER of
infliximab versus etanercept is about 44,000 per QALY. Adalimumab is
extendedly dominated. On average, given the base-case assumptions in the York
model, etanercept would be considered the most cost-effective strategy if the
threshold for cost-effectiveness were 20,000 per QALY or 30,000 per QALY. The
probability etanercept is the most cost-effective treatment is 0.44 at a
threshold of 20,000 per QALY and 0.48 at a threshold of 30,000 per QALY. The
expected lifetime prescription costs of biologic therapies <span class=GramE>is</span>
considerably greater than the offset cost savings elsewhere in the NHS.<o:p></o:p></p>

<p class=MsoNormal>These results are sensitive to several of the scenarios
tested in univariate sensitivity analyses:<o:p></o:p></p>

<p class=MsoNormal>&#61607;<span style='mso-tab-count:1'> </span>All
biologics appear less cost-effective if they are assumed to remain effective
for a maximum of 10 years rather than 40 years, or if HAQ rebounds to NH after
withdrawal.<o:p></o:p></p>

<p class=MsoNormal>&#61607;<span style='mso-tab-count:1'> </span>Results
are sensitive to assumptions about the prescription cost. If three vials of
infliximab are required rather than four, infliximab is much more <span
class=GramE>cost-effective</span> and the other biologics are not
cost-effective.<o:p></o:p></p>

<p class=MsoNormal>&#61607;<span style='mso-tab-count:1'> </span>Results
are sensitive to assumptions about the cost of treating patients who do not
achieve a response to biologics for the psoriasis component of <span
class=SpellE>PsA.</span> If these costs are high, etanercept appears less
cost-effective as it is considerably less effective in treating psoriasis than
the other biologics.<o:p></o:p></p>

<p class=MsoNormal>&#61607;<span style='mso-tab-count:1'> </span>Results
are sensitive to assumptions about the progression of HAQ on and off treatment.
If the prognosis for patients without biologics is worse than the base case, or
HAQ improves while on biologic drugs, all biologics appear more cost-effective.<o:p></o:p></p>

<p class=MsoNormal>&#61607;<span style='mso-tab-count:1'> </span>Results
are sensitive to assumptions about whether clinical effectiveness differs
between the therapies.<o:p></o:p></p>

<p class=MsoNormal>Cost-effectiveness also varies between different subgroups
of patients:<o:p></o:p></p>

<p class=MsoNormal>&#61607;<span style='mso-tab-count:1'> </span>For
patients with PsA and moderate-to-severe skin disease, and who continue with
biologic therapy if they achieve a response for either psoriasis or joint
disease, the ICER of adalimumab versus palliative care is about 16,000 per
QALY, the ICER of etanercept versus adalimumab is about 21,000 per QALY and
the ICER for infliximab versus etanercept is about 26,000 per QALY.<o:p></o:p></p>

<p class=MsoNormal>&#61607;<span style='mso-tab-count:1'> </span>For
patients with PsA and negligible skin involvement, the ICER of etanercept
versus palliative care is about 19,000 per QALY, and the ICER of infliximab
versus etanercept is about 65,000 per QALY. Adalimumab is extendedly dominated
in this group.<o:p></o:p></p>

<p class=MsoNormal>&#61607;<span style='mso-tab-count:1'> </span>For
patients who have failed adalimumab or infliximab as first-line therapy for
either adverse events or inefficacy, etanercept is cost-effective at a
threshold of 20,000 per QALY. For patients who have failed etanercept as
first-line therapy for either adverse events or inefficacy, adalimumab is
cost-effective at a threshold of 20,000 per QALY, though infliximab is more
likely to be cost-effective if the threshold is 30,000 per QALY.<o:p></o:p></p>

<p class=MsoNormal>These are univariate sensitivity and subgroup analyses.
Multivariate sensitivity analyses may lead to different conclusions.<o:p></o:p></p>

<p class=MsoNormal>The decision model and data sources have several limitations
and uncertainties. BAD guidelines recommend that both PASI and DLQI are used to
measure the psoriasis component of <span class=SpellE>PsA.</span><o:p></o:p></p>

<p class=MsoNormal>Few RCTs measured DLQI and so this criterion could not be
used in the decision model. PASI may be less well correlated with <span
class=SpellE>HRQoL</span> than DLQI.194 The decision model assumes that mean
changes in HAQ are a function of <span class=SpellE>PsARC</span> response and
the biologic therapy used. This approach has been used in other decision models
of PsA (see Systematic review of existing cost-effectiveness evidence).152, 177
Changes in HAQ may be more accurately predicted by other clinical and
demographic variables, such as ACR and age. The Abbott model151 estimated a
joint distribution of ACR and <span class=SpellE>PsARC</span>, and predicted
HAQ from ACR responses. Although this is an attractive method, we considered
the evidence synthesis required to undertake this modelling to be very complex
and appeared to use data relating to biologics that are not currently licensed
for PsA (see Systematic review of existing cost-effectiveness evidence).<o:p></o:p></p>

<p class=MsoNormal>There is some debate about whether the RCTs have recruited
similar cohorts of patients and the effect on the results. Our review of the
trial patients' characteristics (see Table 1) indicated that the trials were
similar enough to conduct a meta-analysis, and any resultant treatment
differences were included in the model. However, other experts suggest that
biologic therapies are very similar in their effectiveness and suggest that the
RCTs show superior effects for infliximab only because these trials recruited a
greater proportion of patients with polyarticular disease who may have better
response rates than other types of PsA (Phillip Halliwell, London, UK, 16
February 2010, evidence to NICE committee).<o:p></o:p></p>

<p class=MsoNormal>The base-case model assumes that patients who fail therapy
will be placed on palliative care. In practice many patients are tried with a
second or third biologic. The use of biologics as the second line in a sequence
is explored in a secondary, subgroup analysis. This analysis relies on
non-randomised comparisons and therefore should be considered with caution.<o:p></o:p></p>

<p class=MsoNormal>Some of the patients included in RCTs did not use at least
two DMARDs before trialling a biologic, as recommended by the BSR. In contrast,
data on the NH of PsA without biologic therapy are from an observational study
of rheumatoid factor-negative inflammatory polyarthritis patients with at least
three tender joints and three swollen joints, who have failed at least two
DMARDs.<o:p></o:p></p>

<p class=MsoNormal>Data on withdrawal rates after 3 months are from a
meta-analysis of observational studies. In this model, withdrawal rates are
assumed to be exogenous, i.e. independent of other variables in the model. In
practice, withdrawal may depend on other factors, such as the biologic therapy
used, obtaining a continuing response of both arthritis and psoriasis, and the
options for switching to other biologics. Adverse events are not included in
the model other than through their influence on withdrawal rates in the biologics
register. In practice, there may be longer-term consequences and costs of
adverse events, such as cancers and infections.<o:p></o:p></p>

<p class=MsoNormal>There is little good-quality data on the effect of arthritis
and psoriasis on health-service costs in the UK. The base-case model uses UK
data176 on the effect of HAQ on costs, but is rather dated, the methods used to
analyse the data are not clearly reported and are likely to underestimate the
impact of very severe HAQ on health and Personal Social Services costs. The
base-case model uses data from a UK study of 272 patients with mild-to-moderate
psoriasis to estimate the health service costs if biologics are not used or
patients do not respond to biologics.192 The model uses data from the
Netherlands to estimate the health service costs of treating moderate-to-severe
psoriasis if biologics are not used or patients do not respond to biologics.188<o:p></o:p></p>

<p class=MsoNormal>It is assumed that there is no progression of HAQ for
patients using biologics, based on elicitation of opinion from experts. There
is considerable uncertainty about the rebound of HAQ after withdrawal. The
results of the expert elicitation seemed to indicate that experts believed that
HAQ would rebound by less than the initial gain. This scenario increased the
cost-effectiveness of all biologics, but did not materially change the
conclusions of the model compared with the base case.<o:p></o:p></p>

<p class=MsoNormal>There is uncertainty about how the results of RCTs should be
generalised to clinical practice. The base-case model assumed that the results
in the placebo arm of the trials represented non-pharmacological aspects of
medical care that might not be reproduced outside the trial setting. The
results of the trials were adjusted to take out this placebo effect. An
alternative scenario that assumed these non-pharmacological aspects of medical
care would be generalisable to general practice slightly increased the
cost-effectiveness of all biologics, but did not materially alter the
conclusions of the base-case analysis.<o:p></o:p></p>

<p class=MsoNormal>We compared the results from the current York model with
those of other models<span class=GramE> and, in particular,</span> the industry
submissions to this appraisal. The current York model is essentially very
similar in methods (and results) to the earlier York Assessment Group model
reported by Bravo Vergel et al.177 if there is no skin involvement, the time
horizon is 40 <span class=GramE>years</span> and the HAQ rebound after
withdrawal from biologic is equal to initial gain. Adalimumab was not included
in Bravo Vergel et al. model,177 but the current York model finds that
adalimumab would not be cost-effective in this subgroup.<o:p></o:p></p>

<p class=MsoNormal>Abbott151 (manufacturers of adalimumab) found that
adalimumab has an ICER of just below 30,000 per QALY compared with palliative
care and other biologics are not cost-effective. The Abbott model151 calculated
the average cost-effectiveness of the biologics over all patients with PsA,
40% of whom were assumed not to have psoriasis, and assumed a mean PASI of 6.9
in the 60% of the population with psoriasis. The York model found that for
patients with PsA and mild-to-moderate psoriasis adalimumab is extendedly
dominated and is therefore unlikely to be the most cost-effective treatment.
The reasons for the differences between the York and the Abbott model151 are
difficult to pinpoint, not least because the sources of data for the Abbott151
bivariate evidence synthesis are unclear. Abbott151 estimate a higher response
rate for <span class=SpellE>PsARC</span> and ACR with adalimumab than
etanercept.<o:p></o:p></p>

<p class=MsoNormal>Schering-Plough152 (the manufacturers of infliximab) found
that infliximab was cost-effective for patients of 60 kg weight if vial sharing
is allowed, or if patients use three vials per administration. If vial sharing
is not allowed or patients require four vials per <span class=GramE>administration</span>
then Schering-Plough152 concluded that etanercept was the most cost-effective
strategy at a threshold of 20,000 per QALY in patients without psoriasis and
with psoriasis. These conclusions are broadly consistent with those of the York
model.<o:p></o:p></p>

<p class=MsoNormal>Wyeth153 (the manufacturer of etanercept) found that
etanercept was the most effective and cost-effective <span class=GramE>biologic,
and</span> dominated or extendedly dominated infliximab and adalimumab. This is
not consistent with the results of the York model, which found infliximab to be
the most effective and most costly biologic. The main differences between the
models are likely to be:<o:p></o:p></p>

<p class=MsoNormal>&#61607;<span style='mso-tab-count:1'> </span>The
estimates of <span class=SpellE>PsARC</span> response Wyeth153 found that
etanercept had the highest probability of <span class=SpellE>PsARC</span>
response, whereas the York evidence synthesis (and those of the other
manufacturers) found infliximab to be the most effective for <span
class=SpellE>PsARC</span>.<o:p></o:p></p>

<p class=MsoNormal>&#61607;<span style='mso-tab-count:1'> </span>The
assumption made by Wyeth153 that changes in HAQ are proportional to changes in
PASI This is a strong assumption and Wyeth153 did not provide any clinical
justification to support it.<o:p></o:p></p>

<p class=MsoNormal>Despite the differences in data and model structure outlined
above (see Comparison of the York Economic Assessment with the manufacturers'
models), the results of the York model are broadly consistent with those of
Schering-Plough,152 taking account of assumptions about vial sharing. The
Abbott model151 appears to have overestimated the effectiveness of adalimumab
in terms of <span class=SpellE>PsARC</span> and ACR responses. The Wyeth
model153 appears to have overestimated the effectiveness of etanercept, in
terms of <span class=SpellE>PsARC</span> response, and makes strong and
arguably unjustified assumptions about the relationship between HAQ and PASI.<o:p></o:p></p>

<p class=MsoNormal> 2011, Crown Copyright.<o:p></o:p></p>

<p class=MsoNormal><o:p>&nbsp;</o:p></p>

</div>

</body>

</html>
